**Peter A. Humphrey, M.D., Ph.D.**

**CURRICULUM VITAE**

**Date of Revision:** August 1, 2023

**Name :** Peter A. Humphrey, M.D., Ph.D.

**Appointment** : Professor of Pathology

**School :** Yale University School of Medicine

**Yale University appointment** : March 1, 2014

**Education :**

**B.A.** University of Kansas (Chemistry, Biochemistry) 1978

**Ph.D.** University of Kansas School of Medicine (Biochemistry) 1984

**M.D.** University of Kansas School of Medicine 1984

**Career/Academic Appointments:**

07/1984 – 11/1988 Resident, Anatomic Pathology, Duke University Medical Center, Durham, NC

12/1988 – 06/1992 Assistant Professor, Department of Pathology, Duke University School of Medicine, Durham, NC

07/1992 – 06/2001 Associate Professor of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

07/1994 - 06/2001 Associate Professor of Pathology and Immunology, with tenure, Washington University School of Medicine, St. Louis, MO

07/2006 – 12/2013Ladenson Professor of Pathology and Immunology, with tenure, Washington University School of Medicine, St. Louis, MO

07/2001 – 03/2014 Professor of Pathology and Immunology, with tenure, Washington University School of Medicine, St. Louis, MO

3/2014 – current Professor of Pathology, Yale University School of Medicine

**Administrative Positions:**

2001-2003 Director, Surgical Pathology Fellowship Program, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

2003-2006 Associate Chief, Division of Anatomic Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

2006-2013 Chief, Division of Anatomic Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

2014-current Director of Genitourinary Pathology, Yale School of Medicine, New Haven, CT

**Board Certification :**

American Board of Pathology, Certification in Anatomic Pathology, 1988

Voluntary Re-certification, 2014

**Professional Honors and Recognition (list from most recent to earliest)**

**International/National/Regional**

2013 British Medical Association Award for best book published in Pathology (The Washington Manual of Surgical Pathology, 2nd edition)

2005-2021 Best Doctors in America selection by peers (Best Doctors, Inc.)

1991 Benjamin Castleman Award (from the Massachusetts General Hospital for an outstanding paper in the field of human pathology published in 1990)

1988 The Wiley Forbus Resident Research Award (from the North Carolina Society of Pathologists)

1977 Phi Lambda Upsilon – National Chemistry Honor Society

**University**

2017 The Averill A. Liebow Teaching Award, Department of Pathology, Yale School of Medicine

2013 John M. Kissane Teaching Award for Excellence in Resident Education, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

2007 Installation as first Ladenson Professor of Pathology and Immunology

1996 John M. Kissane Teaching Award for Excellence in Resident Education, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

1992 The Bernard F. Fetter Faculty Teaching Award, Department of Pathology, Duke University Medical Center, Durham, NC

**Grant/Clinical Trials History**

**Past Grants**

Agency : NIH subcontract w/Health Research Inc.

I.D. # RO1 CA132951-02

Title : “Diet change among prostate cancer patients under expectant management”

P.I. James Marshall, MD

Percent effort : Contract basis

Role on project : Co-investigator

Project period : 7/1/11-1/31/16

Agency : Cancer Research Institute

Title: “Immunologic regulation of scatter factor/hepatocyte growth factor during development of prostate cancer”

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 5%

Total costs for project period : $75,000

Project period: 2000-2002

Agency : TJ Martell Foundation

Title: “Scatter factor/hepatocyte growth factor as a serum marker for prostate cancer”

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 5%

Total costs for project period : $20,000

Project period: 2000

Agency : CaP CURE Foundation

Title: “Characterization and stratification of prostatic carcinoma tissues for gene expression screening and gene discovery”

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 5%

Total costs for project period : $100,000

Project period: 1997-1998

Agency : CaP CURE Foundation

Title: “The role of the c-met proto-oncogene in prostatic carcinoma tumorigenesis and metastasis”

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 5%

Total costs for project period : $100,000

Project period: 1995-1996

Agency : NIH

ID : R29 NS29955

Title: “Deletion-mutant EGF receptors in malignant human gliomas”

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 50%

Total costs for project period : $525,000

Project period: 1991-1996

Agency : American Cancer Society

ID # Clinical Oncology Career Development Award # 89-171

Title: “Immunobiology of the epidermal growth factor receptor in malignant human gliomas”

P.I. Peter A. Humphrey, M.D., Ph.D.

Percent effort : 25%

Total costs for project period : $90,000

Project period: 1989-1992

Agency : James S. McDonnell Foundation

ID : Award and Fellowship in Molecular Medicine in Cancer Research

P.I. Peter A. Humphrey, M.D., Ph.D.

Percent effort : 25%

Total costs for project period : $425,000

Project period: 1989-1992

Agency : NIH

ID : National Service Research Award and Public Health Service Post-doctoral Fellow in Immunology

P.I. Peter A. Humphrey, M.D., Ph.D.

Percent effort : 25%

Total costs for project period : $60,000

Project period: 1985-1987

Agency : Association for Brain Tumor Research

ID :Award and Fellowship

P.I. : Peter A. Humphrey, M.D., Ph.D.

Percent effort : 25%

Total costs for project period : $60,000

Project period: 1985-1987

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:**

(list from most recent to earliest)

**International/National**

2023: Florida Society of Pathologists; Palm Beach Florida: Lectures and slide seminar : 1. Prostate Cancer Diagnosis and Grading: 2023 and 5th Edition WHO Update. 2. Kidney Neoplasia: What is New in the 5th Edition WHO Classification. 3. Whole slide images: Variations of Histomorphological Presentation of Cancer Microscopy Slide Session.

2023: Cedars-Sinai (Los Angeles, CA) Pathology Grand Rounds (via Zoom) : False Negative Diagnosis of Malignancy in Surgical Pathology

2023: Lectures at New York GU 16th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, New York – in person: 1. Pathology of Bladder Cancer. 2. Pathology of Renal Cancer with Molecular Subtypes. 3. Pathology of Prostate Cancer.

2022 : University of California – Irvine Urology Zoom Grand Rounds Lecture : Histopathology of Bladder Cancer : Update 2022

2022: Lectures at New York GU 15th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, New York – in person: 1. Pathology of Bladder Cancer. 2. Pathology of Renal Cancer with Molecular Subtypes. 3. Pathology of Prostate Cancer.

2021: Lectures at New York GU 14th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, via live webcast: 1. Pathology of Renal Cancer with Molecular Subtypes. 2. Pathology of Prostate Cancer

2020: Lecture at NIH/NCI SEER Registry and Quality Improvement Expert Meeting, via webcast : Gleason Grading of Prostate Cancer : Changes and Grade Groups

2020: American Society for Clinical Pathology National Meeting: Prostate Problems: Resolving Contemporary Conundrums in Prostate Histopathology, via live virtual session

2020 : University of California – Irvine Urology Zoom Grand Rounds Lecture : Renal Cancer Histopathology

2020: Lectures at New York GU 13th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, via live webcast: 1. Pathology of Renal Cancer with Molecular Subtypes. 2. Pathology of Prostate Cancer

2019: Prostate Pathology lectures at American Society for Clinical Pathology Urological Pathology Course, San Francisco, CA

2019 : Prostate Pathology lectures at 3rd Annual Geisinger Seminar in Anatomic Pathology, Danville, PA

2019 : Genitourinary frozen section teaching sessions at United States and Canadian Academy of Pathology Interactive Microscopy Course, Palm Springs, CA

2019 : University of California – Irvine Urology Zoom Grand Rounds Lecture : Bladder Cancer Histopathology : Update 2019

2019 : 25th Robert M. Nakamura Lectureship at Scripps Green Hospital; Prostate Cancer 2019 : WHO Classification and Risk Assessment

2019: Urologic pathology lectures at Medical University of South Carolina Multi-Specialty Symposium on Surgical Pathology, Kiawah , South Carolina

2018: Prostate Pathology lectures at American Society for Clinical Pathology Urological Pathology Course, Seattle, WA

2018 : Michele Raible Lecture at ASCP National Meeting : Prostate Cancer 2018 Update : WHO Classification and Risk Stratification, Baltimore, MD

2018 : ASCP National Meeting Course : Key Elements in Bladder and Prostate Cancer Biopsy Pathology : New Concepts and Approaches, Baltimore, MD

2018 : Princeton Integrated Pathology Symposium : Genitourinary Pathology. Lecture : “Deceptively Benign-Appearing Prostate Cancers”, Plainsboro, NJ

2018: Grand Rounds Pathology Lecture on Prostate Cancer at Weill Cornell/NY Presbyterian, NY, NY

2017: Prostate Pathology lectures at American Society for Clinical Pathology Urological Pathology Course, Charleston, SC

2017: Pathology Grand Rounds Lecture “High-grade Prostate Cancer : Clinico-pathologic and Molecular Aspects” at University of California, San Diego,

2017: Prostate pathology teaching sessions at United States and Canadian Academy of Pathology Interactive Microscopy Course, Palm Springs, CA

2017: Urologic pathology lectures at Pacific Northwest Society of Pathologists, Vancouver, Canada (keynote speaker)

2017: Urologic pathology lectures at Medical University of South Carolina Multi-Specialty Symposium on Surgical Pathology, Kiawah , South Carolina

2017 : Maude Abbott Lecture at United States and Canadian Academy of Pathology National meeting: “Prostate Cancer : Then and Now”, San Antonio, Texas

*https://www.pathlms.com/uscap/courses/5417/video\_presentations/80683*

2017 : Long course lecture at United States and Canadian Academy of Pathology National meeting : Unusual Variants of Acinar Prostate Cancer Mimicking Benign Conditions”, San Antonio, Texas

2017 : Urologic Pathology lecture, Columbia University, New York Presbyterian Hospital, NY, NY 2016 : Prostate Pathology lectures at American Society for Clinical Pathology Urological Pathology Course, San Diego, CA

2016 : XXXI International Academy of Pathology meeting : “2016 WHO Classification of Tumours of the Prostate”, Cologne, Germany

2016 : South New Jersey Society of Pathologists : “2016 WHO Classification of Urothelial and Prostate Tumors”, Camden , NJ

2016 : Grand Rounds Pathology Lecture at Mount Sinai School of Medicine, NY, NY

2016: Gregory Derringer Grand Rounds Pathology Lecture at Indiana University School of Medicine, Indianapolis, IN

2016 : Grand Rounds Pathology Lecture at New York Medical College, Valhalla, NY

2016 : International Society of Urological Pathology Companion Meeting at United States and Canadian Academy of Pathology : “WHO 2016 Classification of Prostate Tumors” Seattle, WA

2015 : University of California San Francisco 31st Annual Current Issues in Anatomic Pathology Course. “Deceptively Benign-Appearing Prostate Cancer” and “Problem Issues with Gleason Grading of Adenocarcinoma of the Prostate.” San Francisco, California.

2015 : The Pathology of Neoplastic Diseases Course, Memorial Sloan Kettering Cancer Center. “The Evolution of Gleason Grade. Where are we now and Where are we headed.” New York, New York.

2015 : 22nd Annual Seminar in Pathology : Lectures on Core Needle Biopsy of Prostate. Pittsburgh, PA

2015 : International Society of Urological Pathology Companion Meeting at United States and Canadian Academy of Pathology : “Non-Gleason Aspects of Active Surveillance”, Boston, Massachusetts

2015 : University of Zurich Symposium on Recent Advances in Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs : “New Concepts in Prostate Cancer”, Zurich, Switzerland

2015 : Urologic pathology lectures at Pratt-Thomas Symposium on Surgical Pathology, Charleston , South Carolina

2015 : Rhode Island Hospital Pathology Grand Rounds : “Prostate Cancer : Then and Now”, Providence, Rhode Island

2015 : Rhode Island Society of Pathologists : “Surgical Pathology of High-Grade Prostate Cancer”, Providence, Rhode Island

2014: Prostate Pathology lectures at American Society for Clinical Pathology Urological Pathology Course, Santa Fe, NM

2014: Lecture on prostate cancer variants. International Academy of Pathology Meeting, Bangkok, Thailand

2014 : Visiting Professor and Pathology Grand Rounds Lecturer at New York University Medical Center

2014 : Lectures on prostate and kidney cancer at XIIth South Brazilian Congress of Urology, Gramado, Brazil

2014 : Lectures on prostate cancer and slide seminar as Visiting Professor at Wayne State University, Detroit, Michigan

2014 : Lecture on benign mimics of prostate cancer, Nebraska Pathology Association, Omaha, Nebraska

2014: Urologic Pathology lectures at Harvard Medical School Course on Surgical Pathology, Ft. Myers, FL

2014: Lectures and slide seminars at Urological Pathology Course, Hospital del Mar Department of Pathology, Autonomous University of Barcelona School of Medicine, Barcelona, Spain

2013: Lectures at American Society for Clinical Pathology Urological Pathology Course, Las Vegas

2013: Urologic Pathology lectures at Scientific Symposiums Course, Hawaii

2013: Arthur Purdy Stout Lecture at American Society for Clinical Pathology National meeting, Chicago, Illinois

2013: Visiting Professor and Lecturer at Brigham and Women's Hospital Department of Pathology, Harvard Medical School, Boston, MA

2013: Urologic pathology lectures at Pratt-Thomas Symposium on Surgical Pathology, Kiaweh , South Carolina

2013: Urologic pathology lectures at International Society of Urological Pathology/Hong Kong Division of International Academy of Pathology meeting, Hong Kong

2013: Urologic pathology lectures at 39th Annual Florida Society of Pathologists Meeting, Orlando, FL

2012: Urologic pathology lectures at American Society for Clinical Pathology National Meeting, Boston, MA

2012: Lecture at Prostate Pathology Short Course, International Academy of Pathology Meeting, Cape Town, South Africa

2012: Visiting Professor and Lecturer, University of Texas Southwestern, Dallas, Texas

2012: Urologic pathology lectures at Pratt-Thomas Symposium on Surgical Pathology, Kiaweh , South Carolina

2012: Urologic pathology lectures at 3rd Conjoint Surgical Pathology Course by University of Chile, Clinica Las Condes, Massachusetts General Hospital, Santiago, Chile

2012: Urologic Pathology lectures at Harvard Medical School Course on Surgical Pathology, Ft. Myers, FL

2011: Urologic Pathology lectures at Scientific Symposiums Course, Hawaii

2011: Lectures at American Society for Clinical Pathology Urological Pathology Course, Montreal, Canada

2011: Prostate cancer lecture at Russian Society of Pathology meeting, St. Petersburg, Russia

2011: Prostate cancer lecture at Pathology Long Course, International Academy of Pathology Meeting, Helsinki, Finland

2011: Lectures at Harvard Medical School Course on Urologic Surgical Pathology, Boston, MA

2011: Urologic pathology lectures at Pratt-Thomas Symposium on Surgical Pathology, Charleston, South Carolina

2011: Visiting Professor, UCLA. Grand Rounds Lecture : Update on Grading and Staging of Adenocarcinoma of the Prostate, Los Angeles, CA

2010: Lecture "Prostate Pathology Update" at American Society for Clinical Pathology National Meeting, San Francisco, CA

2010: Lecture at Prostate Cancer Pathology Short Course, XXXVIIIth International Academy of Pathology Meeting, Sao Paulo, Brazil

2010: Urologic Pathology lectures, Ontario Association of Pathologists, Niagra Falls, Canada

2010: Urologic Pathology lectures at Scientific Symposiums Course, Hawaii

2010: Lecture “Prostate Pathology Update” American Society for Clinical Pathology Weekend of Pathology, Toronto, Canada

2010: Urologic pathology lectures at Harvard Medical School Course on Urologic Surgical Pathology, Naples, Florida

2010: Urologic pathology lectures at Houston Society of Clinical Pathologists Meeting, Houston, Texas

2010: Canadian Partnership Against Cancer/Canadian Association of Pathologists Webinar : “College of American Pathologists Protocol for the Examination of Specimens from Patients with Carcinoma of the Prostate Gland”

2010: Prostate cancer lecture at Translational Biomedicine Seminar, University of Missouri, Columbia, MO

2009: Lectures at American Society for Clinical Pathology Urological Pathology Course, Santa Fe, NM

2009: Prostate cancer lecture at European Congress of Pathology, Florence, Italy

2009: Lectures at ASCP Surgical Pathology Update Course : GU Pathology, Vancouver, Canada

2009: Prostate cancer lectures at Spanish Association of Pathologists meeting, Seville, Spain

2009: Prostate cancer lecture at New York Pathological Society meeting, NY, NY

2009: Lectures at Harvard Medical School Course on Urologic Surgical Pathology, Newport Beach, CA

2009: Grand Rounds lecture, Yale Department of Pathology, New Haven, CT

2009: Urologic pathology lectures at Oregon Pathology Association, Portland, OR

2008: Lectures at American Society for Clinical Pathology Urological Pathology Course, Palm Springs, CA

2008: Lecture at Prostate Symposium at the 24th International Academy of Pathology Meeting, Athens, Greece

2008: Urologic pathology lectures, The Midwestern Conference. Update in Surgical Pathology, Milwaukee, WI

2008: Lectures, American Society for Clinical Pathology Surgical Pathology Update Course : GU Pathology, Chicago, IL

2008: Urologic pathology lectures at Scientific Symposiums Course, Hilton Head, South Carolina

2008: Urologic pathology lectures at 11th Annual UCSF/Stanford Current Issues in Anatomic Pathology course, San Francisco, CA

2008: Urologic pathology lectures at 2nd Annual Iowa Combined Anatomic Pathology and Cytology Course, Iowa City, Iowa

2008: Prostate cancer lecture at Missouri Pathology Society Meeting, St. Louis, MO

2008: Urologic pathology lectures at Pratt-Thomas Symposium on Surgical Pathology, Charleston, South Carolina

2008: Faculty, Harvard Medical School Course on Urologic Surgical Pathology, Tucson, Arizona

2008: Urologic pathology lectures at University of Miami 33rd Annual Review and Recent Practical Advances in Pathology, Miami, Florida

2007: Visiting Professor and Lecturer “Diagnosis of Minimal Carcinoma of the Prostate”: Brigham and Women’s Hospital, Boston, MA

2007: Prostate cancer lecture at European Congress of Pathology, Istanbul, Turkey

2007: Lectures, American Society for Clinical Pathology Surgical Pathology Update Course : GU Pathology, Montreal, Canada

2007: Urologic pathology lectures 14th Annual Seminar in Pathology, Pittsburgh, Pennsylvania

2007: Faculty, Harvard Medical School Course on Urologic Surgical Pathology, Naples, Florida

2007: Urologic pathology lectures, Pratt-Thomas Symposium on Surgical Pathology, Charleston, South Carolina

2006: Lectures at American Society for Clinical Pathology Course on Urological Pathology, San Antonio, TX

2006: Visiting Professor and lecturer, University of Tennessee, Knoxville, Tennessee

2006: Lecture, video case presentations, and lunch roundtable at American Society for Clinical Pathology National Meeting, Las Vegas, NV

2006: Lectures at Ohio State University 6th Annual Update Course in Surgical Pathology, Columbus, Ohio

2006: Lecture “Unusual Carcinomas in the Prostate” in Long Course at International Academy of Pathology Meeting, Montreal, Canada

2006: Lectures at American Society for Clinical Pathology Surgical Pathology Update Course : GU Pathology. Vancouver, Canada

2006: Gregory Derringer Pathology Grand Rounds, Indiana University School of Medicine : Translational Research in Pathology : Lessons Learned from Prostate Cancer Research, Indianapolis, Indiana

2005: Visiting Professor, University of Virginia. Keynote address at 2ND Annual Research Retreat : “Translational Research in Pathology”, Charlottesville, Virginia

2005: Visiting Professor and lecturer, University of Washington : “Prostate Cancer Diagnosis”, Seattle, WA

2005: Lectures in Course : “Update on Prostate Pathology”, American Society for Clinical Pathology, National Meeting, Seattle, WA

2005: Lectures at course for Tennessee Society of Pathologists : “Contemporary Topics in Surgical Pathology XVIX : Surgical Pathology of the Prostate”, Nashville, TN

2005: Visiting Professor and lecturer, Beth Israel/Deaconess/Harvard : “Tissue-based Prostate Cancer Prognostic Indicators” and resident slide seminar, Boston, MA

2005: Shields Warren Lecture “Minimal Adenocarcinoma of the Prostate” and Evening Case Presentations, New England Society of Pathologists, Boston, MA

2005: Lecture at 4th Asia-Pacific International Academy of Pathology Congress, “Application of Ancillary Studies to Urologic Tumor-like Conditions” Beijing, China

2005: Lectures on Prostate Pathology at Weekends of Pathology, American Society for Clinical Pathology, Las Vegas, NV

2004: Lecture in Prostate Symposium, XXV Congress of the International Academy of Pathology, “Gleason Grading and Prognostic Factors for Carcinoma of the Prostate” : Brisbane, Australia

2004: Lecture at Pathology Mini-symposium, CALGB Group Summer Meeting, “Histomorphological Effects of Neoadjuvant Therapy on Prostatic Carcinoma” Philadelphia, PA

2004: Lecture at Arthur Purdy Stout Society of Surgical Pathologists and USCAP meeting “Bladder Pathology 2004: An Update”, Vancouver, B.C.

2004: Lecture at International Society of Urological Pathology and USCAP meeting, “Application of Ancillary Studies to Urologic Tumor-like Conditions”, Vancouver, B.C.

2004: Callender-Binford Lecture at Armed Forces Institute of Pathology, Diagnosis of Minimal Prostatic Carcinoma”, Washington, D.C.

2004: Lectures and slide seminars at Urological Pathology Course, Hospital del Mar Department of Pathology, Autonomous University of Barcelona School of Medicine, Barcelona, Spain

2003: Lecture at The University of Texas MD Anderson Cancer Center :

“Prostate Cancer : A Study in Heterogeneity”, Houston, TX

2003: Prostate pathology lectures at American Society for Clinical Pathology national meeting and Video Tutorial Session, New Orleans, LA

2003: Lectures at 24th Brazilian Congress of Pathology : “Gleason Grading in Prostate Needle Biopsies” and “Reporting Prognostic Factors in Radical Prostatectomy Specimens”, Florianopolis, Brazil

2003: Visiting Professor and lecturer, Department of Pathology, Weill Medical College, Cornell University, New York, New York

2003: Lectures at American Society for Clinical Pathology Workshop “Update on Pathology of the Prostate”, San Francisco, CA

2003: Co-director and lecturer, Long Course “Prostate Cancer Pathology and Pathobiology”. Talk : Gleason Grading and Prognostic Factors”, United States and Canadian Academy of Pathology Annual Meeting, Washington, D.C.

2003: Lectures at American Society for Clinical Pathology Weekend in Pathology Course “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies”, Las Vegas, NV

2002: Pathology Grand Rounds at The University of Texas MD Anderson Cancer Center : “Prostatic Carcinoma : From Pseudobenign Proliferations to Paracrine Growth Control”, Houston, TX

2002: Lectures at Jack Gordon Annual Pathology Symposium :”New Classification of Urinary Bladder Papillary Neoplasms” and “Small Volume Prostate Cancer- When to Diagnose and How to Manage”, Long Beach, CA

2002: Lecture at Pacific Northwest Society of Pathologists Meeting : “Diagnosis of Minimal Prostate Cancer”, Skamania, WA

2002: Lectures at American Society for Clinical Pathology Workshop “Update on Pathology of the Prostate”, Toronto Canada

2002: Lectures at United States and Canadian Academy (USCAP)Pathology Short Course “Contemporary Issues in Prostatic and Urinary Tract Pathology: An Interactive Seminar” at USCAP National Meeting, Chicago, IL

2001: Lectures in American Society for Clinical Pathology Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP National Meeting, Philadelphia, PA

2001: Lecture at Emory University : “Approach to Diagnosis of Minimal Adenocarcinoma in Prostate Needle Biopsy Tissue”, Atlanta, GA

2000: Lectures in American Society for Clinical Pathology (ASCP) Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP National Meeting, San Diego, CA

1999: Urologic Pathology Lectures at Alabama Association of Pathology, Birmingham, AL

1999: Lectures in American Society for Clinical Pathology Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP National Meeting, New Orleans, LA

1999: Lectures in American Society for Clinical Pathology (ASCP) Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP Weekend of Pathology, Las Vegas

1998: Lectures in ASCP Course: “Diagnostic Dilemmas in Urologic Pathology” in Selected Topics in Surgical Pathology, Chicago, IL

1998: Lectures in American Society for Clinical Pathology (ASCP) Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP Spring National Meeting, Los Angeles, CA

1998: Lectures in American Society of Clinical Pathology (ASCP)Workshop “Focal Atypical Epithelial Proliferations in Prostate Needle Biopsies” at ASCP Weekend of Pathology, Coral Gables, FL

1997: Lectures at Venezuela Congress of Prostate Diseases, Caracas, Venezuela

1997: Pathology Grand Rounds , Memorial Sloan-Kettering Cancer Center, New York: “Prostatic Carcinoma: From Diagnostic Dilemmas to Paracrine Growth Control”, NY, NY

1996: Prostate cancer lecture at Huntsman Cancer Institute, University of Utah,

Salt Lake City, NV

1994: Prostate cancer lecture at American Cancer Society National Conference on Prostate Cancer, Philadelphia, PA

1994: Lecture at First International Consultation Meeting on Prostatic Intraepithelial Neoplasia, Ancona, Italy

1993: Dowling Lectureship on prostatic intraepithelial neoplasia, University of South Alabama

1992: Lecture on epidermal growth factor receptor, Department of Biochemistry, Kansas University Medical Center, Kansas City, KS

1992: Speaker at 87th Annual Meeting, American Urological Association, Residents' Luncheon, Selected Prostate and Bladder Cancer Cases, San Antonio, TX

1991 : Lecture on epidermal growth factor receptor, Ninth International Conference on Brain Tumor Research and Therapy, Monterey, CA

1990: University of Missouri, Department of Surgery Grand Rounds, “Epidermal growth factor receptor in gliomas”, Columbia, MO

1990: Lecture on the epidermal growth factor receptor at The Society of Nuclear Medicine national meeting, Washington, DC

1990: American Society of Clinical Pathology Teleconference: “Sarcomatoid Carcinoma”, Durham, NC

1989: Lecture on monoclonal antibody Fab fragments at Eighth International Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland

**Professional Service**

**Peer Review Groups/Grant Study Sections : (list from most recent to earliest)**

2010:Reviewer, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs

2008-2010: Member, External Advisory Committee, Creighton University Cancer and Smoking Disease Research Program

2000-2008, 1995,1996, 1998 NCI Ad Hoc Reviewer

2002, 2000, 1998: Member, Department of Defense Prostate Cancer Review Committee, Pathobiology Section

1989-1991: NIH Pathology A Study Section Ad Hoc Reviewer

**Journal Service**

Editor/Associate Editor

2020-2022 Associate Editor, *Modern Pathology*

2000-2017 Surgical Pathology Section Editor, *American Journal of Clinical Pathology*

2011-2015 Editor, Pathology Page, *The* *Journal of Urology*

Editorial Board Membership

1998-present *The American Journal of Surgical Pathology*

2000-present *Human Pathology*

2000-2022 *Modern Pathology*

2005-present *Annals of Diagnostic Pathology*

2021-present *Journal of Pathology and Translational Medicine*

Ad Hoc reviewer :

*Cancer, Urology, Journal of Urology, Archives of Pathology and*

*Laboratory Medicine, American Journal of Pathology, Clinical Cancer Research, The Journal of Molecular Diagnostics, British Journal of Urology International, Cancer Research, International Journal of Surgical Pathology, Human Pathology, Proceedings of the National Academy of Sciences, Journal of Clinical Oncology*

**Professional Service for Professional Organizations (list from most recent to earliest)**

***Arthur Purdy Stout Society of Surgical Pathologists***

2015-2017 President, Arthur Purdy Stout Society of Surgical Pathologists

2013-2015 President-elect, Arthur Purdy Stout Society of Surgical Pathologists

2009-2014 Treasurer, Arthur Purdy Stout Society of Surgical Pathologists

2007-2014 Member, Council of Arthur Purdy Stout Society of Surgical Pathologists

***International Society of Urological Pathology***

2013-2015 President, International Society of Urological Pathology

2011-2013 President-elect, International Society of Urological Pathology

***Association of Directors of Anatomic and Surgical Pathology***

2012-2014 President, Association of Directors of Anatomic and Surgical Pathology

2005-2012 Member, Association of Directors of Anatomic and Surgical Pathology Council

***United States and Canadian Academy of Pathology***

2006-2009 Member, Council, United States and Canadian Academy of Pathology

2003-2005 Member, Nominating Committee, United States and Canadian Academy of Pathology

1998-2002 Member, Education Committee, United States and Canadian Academy of Pathology

***College of American Pathologists***

2006-2010 Member, Cancer Committee, College of American Pathologists

***American Society for Clinical Pathology***

2004-2008 Member, Education Commission, American Society of Clinical Pathology

2004-2005 Member, Publications Commission, American Society of Clinical Pathology

***American College of Surgeons***

1998-2003 Member, American College of Surgeons - Oncology Group, Genitourinary Committee

***Cancer and Leukemia Group B*** (National cooperative oncology group)

1997-2006 Cadre Leader, Prostate Pathology

***Yale University Service : (list from most recent to earliest)***

2016-2019 Senior Appointments and Promotions Committee, Yale School of Medicine

**Bibliography**(listed from earliest to most recent and numbered consecutively)

Scopus *h*-index: 89

Google scholar h-index: 103

1. Panoussopoulos DG, **Humphrey PA**, Humphrey LJ, Meek J: Effect of various thyroid states on immunity. *Surg Forum* 1976;27:138-140.

2. Necessary PC, **Humphrey PA**, Mahajan PB, Ebner KE: Purification of rabbit mammary prolactin receptor by acidic elution from a prolactin affinity column. *J Biol Chem* 1984;259:6942-6946.

3. Necessary PC, Roberts B, **Humphrey PA**, Helmkamp Jr GM, Turner CD, Rawitch AB, Ebner KE: The Cuisinart food processor efficiently disaggregates tissues. *Anal Biochem* 1985;146:372-373.

4. Bullard DE, Wikstrand CJ, **Humphrey PA**, Lee YS, Coleman RE, Zalutsky M, Bigner DD: Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). *Nucl Med* 1986;25:210-215.

5. **Humphrey PA**, Scroggs MW, Roggli VL, Shelburne JD: Pulmonary carcinomas with a sarcomatoid element: An immunocytochemical and ultrastructural analysis. *Hum Pathol* 1988;19:155-164.

6. **Humphrey P**, Vollmer RT: The ratio of prostate chips with cancer: A new measure of tumor extent and its relationship to grade and prognosis. *Hum Pathol* 1988;19:411- 418.

7. Lee Y, Bullard DE, **Humphrey PA,** Colapinto EV, Friedman HS, Zalutsky MR, Coleman RE, Bigner DD: Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. *Cancer Res* 1988;48:2904-2910.

8. **Humphrey PA**, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. *Cancer Res* 1988;48:2231-2238.

9. Colapinto EV, Lee Y, **Humphrey PA**, Zalutsky MR, Friedman HS, Bullard DE, Bigner DD: The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.  *Br J Neurosurg* 1988;2:179-191.

10. Werner MH, **Humphrey PA,** Bigner DD, Bigner SH: Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. *Acta Neuropathol* 1988;77:196-201.

11. Colapinto EV, **Humphrey PA**, Zalutsky MR, Groothuis DR, Friedman HS, de Tribolet N, Carrel S, Bigner DD: Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole Ig2a in human glioma xenografts. *Cancer Res* 1988;48:5701-5707.

12. **Humphrey PA**, Ingram P, Tucker A, Shelburne JD: Crystalloids in salivary gland pleomorphic adenomas. *Arch Pathol Lab Med* 1989;113:390-393.

13. **Humphrey PA**, Wong AJ, Vogelstein B, Zalutsky MR, Fuller N, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. *Proc Natl Acad Sci USA* 1990;87:4207-4211.

14**. Humphrey PA**, Vollmer RT: Intraglandular tumor extent and prognosis in prostatic carcinoma: Application of a grid method to prostatectomy specimens. *Hum Pathol* 1990;21:799-804.

15. **Humphrey PA**, Vollmer RT: Corpora amylacea in adenocarcinoma of the prostate: Prevalence in 100 prostatectomies and clinicopathologic correlations*. Surg Pathol* 1990;3:133-141.

16. Lund-Johansen M, Bjerkvig R, **Humphrey PA,** Bigner SH, Bigner DD, Laerum O-D: Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. *Cancer Res* 1990;50:6039-6044.

17. Bigner SH, **Humphrey PA**, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. *Cancer Res* 1990;50:8017-8022.

18. Marks JR, Davidoff AM, Kerns BJ, **Humphrey PA**, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. *Cancer Res* 1991;51:2979-2984.

19. Davidoff AM, **Humphrey PA**, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. *Proc Natl Acad Sci USA* 1991;88:5006-5010.

20. Ostrowski LE, Pegram CN, von Wronski MA, **Humphrey PA**, He X, Shiota S, Mitra S, Brent TP, Bigner DD: Production and characterization of antipeptide antibodies against human O6-methylguanine-DNA methyltransferase. *Cancer Res* 1991;51:3339-3344.

21.  **Humphrey PA**: Mucin in severe dysplasia in the prostate. *Surg Pathol* 1991;4:137-143.

22. **Humphrey PA**, Gangarosa LM, Wong AJ, Archer GE, Lund-Johansen M, Bjerkvig R, Laerum O-D, Friedman HS, Bigner DD: Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function. *Biochem Biophys Res Commun* 1991;178:1413-1420.

23. **Humphrey PA**, Walther PJ, Currin SM, Vollmer RT: Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma: A direct comparison. *Am J Surg Pathol* 1991;15:1165-1170.

24. Frazier HA, **Humphrey PA**, Burchette JL, Paulson DF: Immunoreactive prostatic specific antigen in male periurethral glands*. J Urol* 1992;147:246-248.

25. Wiener JS, Effert PJ, **Humphrey PA**, Yu L, Liu ET, Walther PJ: Prevalence of human papillomavirus types 16 and 18 in squamous-cell carcinoma of the penis: A retrospective analysis of primary and metastatic lesions by differential polymerase chain reaction. *Int J Cancer* 1992;50:694-701.

26. Kohler MF, Berchuck A, Davidoff AM, **Humphrey PA**, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast Jr RC, Marks JR: Overexpression and mutation of p53 in endometrial carcinoma. *Cancer Res* 1992;52:1622-1627.

27. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, **Humphrey PA**, Bigner DD, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. *Proc Natl Acad Sci USA* 1992;89:2965-2969.

28. Kerns B-JM, Jordan PA, Moore M-BH, **Humphrey PA**, Berchuck A, Kohler MF, Bast Jr RC, Iglehart JD, Marks JR: p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry*. J Histochem Cytochem* 1992;40:1047-1051.

29. Ibrahim GK, MacDonald JA, Kerns BM, Ibrahim SN, **Humphrey PA**, Robertson CN: Differential immunoreactivity of HER-2/Neu oncoprotein in benign, dysplastic, and malignant prostatic tissues. *Surg Oncol* 1992;1:151-155.

30. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, **Humphrey P**, Berchuck A, Ponder BAJ, Bast RC Jr: Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-1798.

31. Ibrahim GK, Kerns BJM, MacDonald JA, Ibrahim SN, Kinney RB, **Humphrey PA**, Robertson CN: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 1993;149:170-173.

32. Frazier HA, Robertson JE, **Humphrey PA**, Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-518.

33. **Humphrey PA**, Frazier HA, Vollmer RT, Paulson DF: Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate specific antigen levels. Cancer 1993;71:1821-1827.

34. **Humphrey PA**: Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Pathol 1993;17:468-472 .

35. Udvadia AJ, Rogers KT, Higgins PDR, Murata Y, Martin KH, **Humphrey PA**, Horowitz JM: Sp-1 binds promoter elements regulated by the Rb protein and Sp-1 mediated transcription is stimulated by Rb co-expression.  *Proc Natl Acad Sci USA* 1993;90:3265-3269.

36. Bostwick DG, Srigley J, Grignon D, Maksem J, **Humphrey PA**, van der Kwast T, Bose D, Harrison J, Young RH: Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. *Hum Pathol* 1993;24:819-832.

37. Swanson PE, **Humphrey PA**, Dehner LP: Immunoreactivity for bcl-2 protein in peripheral primitive neuroectodermal tumors. *Appl Immunohistochem* 1993;1:182-187.

38. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, **Humphrey PA**: Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. *Hum Pathol* 1993;24:982-989.

39. Wikstrand CJ, Stanley SD, **Humphrey PA**, Pegram CN, Archer GE, Kurpad S, Shibuya M, Bigner DD: Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. *J Neuroimmunol* 1993;46:165-174.

40. Kohler MF, Kerns B-JM, Soper JT, **Humphrey PA**, Marks JR, Bast RC Jr, Berchuck A: Mutation and overexpression of p53 in early stage epithelial ovarian cancer. *Obstet Gynecol* 1993;81:643-650.

41. Kohler MF, Nishii M, **Humphrey PA**, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A: Mutation of the p53 tumor suppressor gene is not a feature of endometrial hyperplasias. *Am J Obstet Gynecol* 1993;169:690-694.

42. Berchuck A, Kohler MF, Hopkins MP, **Humphrey PA**, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Jr.: Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. *Gynecol Oncol* 1994;52:232-236.

43. **Humphrey PA**, Franquemont DW, Geary WA, Kerns B-JM, Iglehart JD, Marks JR: Immunodetection of p53 protein in non-invasive epithelial proliferative breast disease. *Appl Immunohistochem* 1994;2:15-21.

44. Keetch DW**, Humphrey PA**, Ratliff TL: Development of a mouse model for nonbacterial prostatitis. *J Urol* 1994;152:247-250.

45. Marks JR, **Humphrey PA**, Wu K, Berry D, Bandarenko N, Kerns B-JM, Iglehart JD: Overexpression of the p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. *Ann Surg* 1994;219:332-341.

46. Day M, Xin Z, Wu S, Swanson P, **Humphrey PA**: Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. *Cell Growth Diff* 1994;5:735-741.

47. Pearle MS, Moon YT, Endicott RC, Gardner SM, **Humphrey P**, Clayman RV: Comparison of retrograde endo-pyelotomy and endo-balloon rupture of uteropelvic junction in porcine model. *J Urol* 1994;6:2232-2239.

48. Hudson MA, Swanson PE, Nadler RB, **Humphrey PA**: p53 protein accumulation in superficial bladder cancer is a predictor of subsequent muscle invasion.  *J Urol Pathol* 1994;2:307-318.

49. Moon YT, Kerbl K, Pearle MS, Gardner SM, McDougall EM, **Humphrey P**, Clayman RV: Evaluation of optimal stent size after endourologic incision of ureteral strictures*. J Endourol* 1995;9:15-22.

50. **Humphrey PA**, Baty J, Keetch D: Relationship between serum prostate-specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. *Cancer* 1995;75:1842-1849.

51. Keetch DW, **Humphrey PA**, Stahl D, Smith DS, Catalona WJ: Morphometric analysis and clinical follow-up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate*. J Urol* 1995;154:347-351.

52. Nadler RB, **Humphrey PA**, Smith DS, Catalona WJ, Ratliff TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. *J Urol* 1995;154:407-413.

53. Gardner SM, Clayman RV, McDougall EM, Moon YT, Fadden P, Anderson KR, Pearle MS, Royal H, **Humphrey PA,** Dingleton E, Roemer F: Laparoscopic pneumodissection: A unique means of tissue dissection. *J Urol* 1995;154:591-594.

54. Wikstrand CJ, Hale LP, Batra SK, Hill ML, **Humphrey PA**, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalatsky MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. *Cancer Res* 1995;55:3140-3148.

55. Epstein JI, Grignon DJ, **Humphrey PA**, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM: Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. *Am J Surg Pathol* 1995;19:873-886.

56. **Humphrey PA**, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. *Am J Pathol* 1995;147:386-396.

57. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, **Humphrey PA**, Friedman HS, Bigner DD: Epidermal growth factor receptor ligand-independent unregulated cell transforming potential of a naturally occurring human mutant EGFRvIII gene. *Cell Growth Diff* 1995;6:1251-1259.

58. **Humphrey PA**, Swanson PE: Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. *Path Res Pract* 1995;191:881-887.

59. **Humphrey PA**, Keetch DW, Smith DS, Shepherd DL, Catalona WJ: Prospective characterization of pathologic features of prostatic carcinomas detected via serum prostate specific antigen-based screening. *J Urol* 1996;155:816-820.

60. McDougall EM, Mark TG, Wolf SJ Jr., Hicks M, Clayman RV, Gardner S, **Humphrey PA**, Sharp T, Martin K: The effect of prolonged pneumoperitoneum on renal function in an animal model. *J Am Coll Surg* 1996;182:317-328.

61. Keetch DW, **Humphrey PA**, Smith DS, Stahl D, Catalona WJ: Clinical and pathologic features of hereditary prostate cancer. *J Urol* 1996;155:1841-1843.

62. Shepherd D, Keetch DW, **Humphrey PA**, Smith DS, Stahl D: Rebiopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. *J Urol* 1996;156:460-463.

63. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, **Humphrey PA**, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. *Urology* 1996;48:47-57.

64. Gardner SM, Wolf JS Jr, Nakada SY, Moon YT, Figenshau RS, Pearle MS, Soble JJ, **Humphrey PA**, Clayman RV: Unintubated ureterotomy endourologically revisited. *J Urol* 1996;156:1160-1163.

65. Nakada SY, Soble JJ, Gardner SM, Wolf JS Jr, Figenshau RS, Pearle MS, **Humphrey PA**, Clayman RV: Comparison of acucise endopyelotomy and endoballoon rupture for management of secondary proximal ureteral stricture in the porcine model*. J Endourol* 1996;10:311-318

66. Wolf JS Jr, **Humphrey PA**, Rayala HJ, Gardner SM, Mackey B: Comparative ureteral microanatomy. *J Endourol* 1996; 10:527-531.

67. Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J, Paoletti E, **Humphrey PA**, Harmon TJ, Ratliff TL: Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. *J Natl Cancer Inst* 1997;89:428-436.

68. Marley EF, Liapis H, **Humphrey PA**, Nadler RB, Siegel CL, Zhu X, Brandt JM, Dehner LP: Primitive neuroectodermal tumor of the kidney: Another enigma. A pathologic, immunohistochemical and molecular diagnostic study. *Am J Surg Pathol* 1997;21:354-359.

69. **Humphrey PA**, Vollmer RT: Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. *Mod Pathol* 1997; 10:326-333.

70. Wolf JS Jr, Soble JJ, Nakada SY, Rayala HJ, **Humphrey PA**, Clayman RV, Poppas DP: Comparison of fibrin glue, laser weld, and mechanical suturing device for the laparoscopic closure of ureterotomy in a porcine model. *J Urol* 1997;157:1487-1492.

71. Day ML, Foster RG, Day KC, Zhao X, **Humphrey P**, Swanson P, Postigo AA, Zhang SH, Dean DC: Cell anchorage regulates apoptosis through retinoblastoma tumor suppressor/E2F pathway*. J Biol Chem* 1997;272:8125-8128.

72. Ritter JH Wick MR, Adesokan PN, Fitzgibbon JF, Zhu X, **Humphrey PA**: Assessment of clonality in cutaneous lymphoid infiltrates by polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangement. *Am J Clin Pathol* 1997;108:60-68.

73. Henneberry JM, Kahane H, **Humphrey PA**, Keetch DW, Epstein JI: The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. *Am J Surg Pathol* 1997;21:725-728.

74. Wolf JS Jr, Rayala HJ, **Humphrey PA,** Clayman RV: In vivo comparison of electrosurgical vaporization electrodes. *J Endourol* 1997;11:83-87.

75. McDougall EM, Elashry OM, Clayman RV, **Humphrey PA**, Rayala HJ: Laparoscopic pyeloplasty in the animal model. *J Soc Lap Surg* 1997;1:113-118.

76. Reyes AO, Swanson PE, Carbone JM, **Humphrey PA**: Unusual histologic types of high-grade prostatic intraepithelial neoplasia. *Am J Surg Pathol* 1997; 21:1215-1222.

77. Siegel CL, McFarland EG, Brink JA, Fisher RJ, **Humphrey PA**, Heiken JP: CT of cystic renal masses: analysis of diagnostic performance and interobserver variation. *Am J Roent* 1997; 169:813-818.

78. McDougall EM, Robinson O, Maxwell KL, **Humphrey PA**, Rayala HJ, Clayman RV: Effect of mineral oil on porcine urothelium*. J Endourol* 1997; 11:177-179.

79. Vollmer RT, **Humphrey PA**, Swanson PE, Wick MR, Hudson MA : Invasion of the bladder by transitional cell carcinoma : Its relation to histologic grade, p53, MIB-1,c-erbB-2, epidermal growth factor receptor, and bcl-2. *Cancer* 1998; 82: 715-723.

80. Ornstein DK, Smith DS, **Humphrey PA**, Catalona WJ : The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. *J Urol* 1998; 159:1234-1237.

81. Reyes AO, **Humphrey PA**: Diagnostic effect of complete histologic sampling of prostate needle biopsies. *Am J Clin Pathol* 1998; 109:416-422.

82. Kaleem Z, Swanson PE, Vollmer RT, **Humphrey PA**: Prostatic adenocarcinoma with atrophic features: A study of 202 consecutive, completely-embedded radical prostatectomy specimens. *Am J Clin Pathol* 1998; 109:695-703.

83. Arcangeli CG, **Humphrey PA,** Smith DS, Harmon TZ, Shepherd DL, Keetch DW, Catalona WJ: Percentage of free serum prostate-specific antigen as a predictor of pathological features of prostate cancer in a screening population. *Urology* 1998; 51:558-564.

84. Kaleem Z, Lind AC, **Humphrey PA**, Swanson PE, Sueper RH, Ritter JH, Wick MR : Immunohistologic evaluation of putatively-mutant p53 protein in cutaneous melanocytic neoplasms. *Int J Surg Pathol* 1998; 6:73-80.

85. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, **Humphrey PA**: Minimal carcinoma in prostate needle biopsy specimens: Diagnostic features and radical prostatectomy follow-up. *Mod Pathol* 1998; 11:543-551.

86. Jones TR, **Humphrey PA**, Brennan DC: Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in a renal transplant patient. *Transplantation* 1998; 65:1605-1610.

87. Maxwell KL, McDougall EM, Shalhav AL, Elbahnasy AM, Hoenig DM**, Humphrey PA**, Clayman RV: Laparoscopic ureteroureterostomy using vascular closure staples in porcine model*. J Endourol* 1998; 12:265-268.

88. **Humphrey PA**, Kaleem Z, Swanson PE, Vollmer RT : Pseudohyperplastic prostatic adenocarcinoma. *Am J Surg Pathol* 1998; 22 :1239-1246.

89. O’Sullivan MJ, Ritter JH, **Humphrey PA**, Wick MR: Lymphoid lesions of the gastrointestinal tract. A histologic, immunophenotypic, and genotypic analysis of 49 cases*. Am J Clin Pathol* 1998; 110:471-477.

90. Vollmer RT, Keetch DW, **Humphrey PA**: Prediction of pathology results of radical prostatectomy from preoperative information: A validation study. *Cancer* 1998; 83:1567-1580.

91. Naughton CK, Smith DS, **Humphrey PA**, Catalona WJ, Keetch DW : Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores : A retrospective study. *Urology* 1998; 52 : 808-813.

92. Garabedian EM, **Humphrey PA**, Gordon JI : A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. *Proc Natl Acad Sci* 1998; 95 : 15382-15387.

93. Brewer AV, McDougall EM, Elbahnasy AM, Shalhav AL, Maxwell KL, Kovacs G, Hoenig DM, **Humphrey PA**, Clayman RV : Improved instrumentation to facilitate laparoscopic ureteroureterostomy. *Min Invas Ther & Allied Technol* 1999;8 : 19-24.

94. Doll JA, Zhu X, Furman J, Kaleem Z, Torres C, **Humphrey PA**, Donis-Keller H : Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis). *Am J Pathol* 1999;155:967-972.

95. Kaleem Z, Lind AC, **Humphrey PA**, Sueper RH, Swanson PE, Ritter JH, Wick MR : Concurrent Ki-67 and p-53 immunolabeling in cutaneous melanocytic neoplasms: An adjunct for recognition of the vertical growth phase in malignant melanomas? *Mod Pathol* 2000; 13:217-222.

96. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, **Humphrey PA**, Catalona WJ, Milbrandt J : Tissue factor expression and angiogenesis in human prostate carcinoma. *Hum Pathol* 2000; 31 : 443-447.

97. Portis AJ, Elbahnasy AM, Shalhav AL, Brewer AV, Olweny E, **Humphrey PA**, McDougall EM, Clayman RV : Laparoscopic midsagittal hemicystectomy and replacement of bladder wall with small intestinal submucosa and reimplantation of ureter into graft.  *J Endourol* 2000; 14 ; 203-211.

98. Cook JR, Hill A, **Humphrey PA**, Pfeifer JD, El-Mofty SK : Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement : Emerging common pattern of clinical features and human papillomavirus serotype association. *Mod Pathol* 2000; 13 : 914-918..

99. Hill AD, Pfeifer JD, Marley EF, Dehner LP, **Humphrey PA**, Zhu X, Swanson PE : WT-1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor : An immunohistochemical and molecular diagnostic study. *Am J Clin Pathol* 2000; 114:345-353.

100. Gokden N, Nappi O, Swanson PE, Pfeifer JD, Vollmer RT, Wick MR, **Humphrey PA** : Renal cell carcinoma with rhabdoid features. *Am J Surg Pathol* 2000; 24:1329-1338.

101. Carvalhal GF, **Humphrey PA**, Thorson P, Yan Y, Ramos CG, Catalona WJ : Visual estimate of percentage of cancer is an independent predictor of prostate cancer recurrence after radical prostatectomy. *Cancer* 2000; 89:1308-1314.

102. Olweny EO, Portis AJ, Sundaram CP, Afane JS, **Humphrey PA**, Ewers R, McDougall EM, Clayman RV : Evaluation of a chronic indwelling prototype mesh ureteral stent in a porcine model. *Urology* 2000; 56 : 857-862.

103. O’Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, **Humphrey PA**, Pfeifer JD : Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. *Mod Pathol* 2000; 13:1336-1346.

104. Zhu X, **Humphrey PA** : Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. *Urology* 2000; 56:1071-1074.

105. Abdulkadir SA, Qu Z, Garabedian E, Song S-K, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JH, Gordon JI, **Humphrey PA**, Milbrandt J : Impaired prostate tumorigenesis in Egr-1-deficient mice. *Nature Med* 2001; 7:101-107.

106. Sarangarajan R, Hill DA, **Humphrey PA**, Hitchcock MG, Dehner LP, Pfeifer JD : Primitive neuroectodermal tumors of the biliary and gastrointestinal tracts : Clinicopathologic and molecular diagnostic study of two cases. *Ped Develop Pathol* 2001; 4 :185-191.

107. Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, **Humphrey PA**, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI : Interobserver reproducibility of Gleason grading of prostatic carcinoma:Urologic pathologists. *Hum Pathol* 2001; 32:74-80.

108. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, **Humphrey PA** : Scatter factor/hepatocyte growth factor elevation in the serum of prostate cancer patients. *J Urol* 2001; 165:1325-1328.

109. Ylagan LR, **Humphrey PA** : Micropapillary variant of transitional cell carcinoma of the urinary bladder : cytologic diagnosis in urine specimens. *Acta Cytol* 2001; 45:599-604.

110. Magee JA, Araki T, Patil S, Ehrig T, True L, **Humphrey PA**, Catalona WJ, Watson MA, Milbrandt J : Expression profiling reveals hepsin overexpresssion in prostate cancer. *Cancer Res* 2001; 61:5692-5696.

111. Abdulkadir SA, Carbone JM, Naughton CK, **Humphrey PA**, Catalona WJ, Milbrandt J : Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. *Hum Pathol* 2001; 32:935-939.

112. Vollmer RT, **Humphrey PA**: The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. *Am J Clin Pathol* 2001; 116:864-870.

113. Fuller CE, Pfeifer J, **Humphrey PA**, Bruch LA, Dehner LP, Perry A: Chromosome 22q dosage in composite extrarenal rhabdoid tumors : clonal evolution or a phenotypic mimic? *Hum Pathol* 2001; 32:1102-1108.

114. O’Sullivan MJ, Perlman EJ, Furman J, **Humphrey PA**, Dehner LP, Pfeifer JD : Visceral primitive peripheral neuroectodermal tumors: A clinicopathologic and molecular study. *Hum Pathol* 2001; 32:1109-1115.

115. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, **Humphrey PA**, Milbrandt J : Conditional loss of nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. *Mol Cell Biol* 2002; 22:1495-1502.

116. Copeland JN, Amin MB, **Humphrey PA**, Tamboli P, Ro J, Gal AA: The morphologic spectrum of metastatic prostatic adenocarcinoma to the lung : special emphasis on histologic features overlapping with other pulmonary neoplasms. *Am J Clin Pathol* 2002; 117: 552-557.

117. Lewis JS Jr, Vollmer RT, **Humphrey PA** : Prostate needle biopsy carcinoma extent in the prediction of whole gland tumor volume in a screening population. *Am J Clin Pathol* 2002; 4:178-180.

118. Yan Y, Andriole GL, Humphrey PA, Kibel AS : Patterns of multiple recurrences of superficial (Ta/T1) TCC of bladder and effects of clinicopathological and biochemical factors. *Cancer* 2002, 95:1239-1246.

119. Hill DA, O’Sullivan MJ, Zhu X, Vollmer RT, **Humphrey PA**, Dehner LP, Pfeifer JD : Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas. A prospective study. *Am J Surg Pathol* 2002; 26:965-977.

120. O’Sullivan MJ, **Humphrey PA**, Dehner LP, Pfeifer JD : t(X;18) reverse transcriptase-polymerase chain reaction demonstrating a variant transcript.  *J Mol Diagn* 2002; 4:178-180.

121. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, **Humphrey PA**, Roehl KA, Catalona WJ: Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. *Urology* 2002; 60:469-474.

122. Hu Y, Ippolito JE, Garabedian EM, **Humphrey PA**, Gordon JI : Molecular characterization of a metastatic neuroendocrine cancer arising in the prostates of transgenic mice*. J Biol Chem* 2002; 277:44462-44474.

123. Landman J, Sundaram CP, Bhayani S, Monga M, Pattaras JG, Gokden N, **Humphrey PA**, Clayman RV: Renal hypothermia achieved by retrograde intracavitary saline perfusion*. J Endourol* 2002; 16:445-449.

124. Vollmer RT, **Humphrey PA**: Tumor volume in prostate cancer and serum prostate-specific antigen : analysis from a kinetic viewpoint. *Am J Clin Pathol* 2003; 119: 80-89.

125. Bismar TA, Lewis JS Jr, Vollmer RT, **Humphrey PA** : Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. *Am J Surg Pathol* 2003; 27:432-440.

126. Landman J, Kerbl K, Rehman J, Andreoni C, **Humphrey PA**, Collyer W, Olweny E, Sundaram C, Clayman RV: Evaluation of a vessel sealing system, bipolar electrosurgery, harmonic scalpel, titanium clips, endoscopic gastrointestinal anastomosis vascular staples and sutures for arterial and venous ligation in a porcine model. *J Urol* 2003; 169:697-700.

127. Sheir KZ, Lee D, **Humphrey PA**, Morrissey K, Sundaram CP, Clayman RV: Evaluation of synchronous twin pulse technique for shock wave lithotripsy : in vivo tissue effects. *Urology* 2003; 62:964-967.

128. Thorson P, Swanson P, Vollmer RT, **Humphrey PA** : Basal cell hyperplasia in the peripheral zone of the prostate. *Mod Pathol* 2003; 16:598-606.

129. Shappel SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, **Humphrey PA**, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD: Prostate pathology of genetically engineered mice : Definitions and classification. The consensus report from the Bar Harbor Meeting of the mouse models of human cancer consortium prostate pathology committee. *Cancer Res* 2004; 64:2270-2305.

130. Bismar TA, **Humphrey PA**, Grignon DJ, Wang, H : Expression of β-Catenin in prostatic adenocarcinoma. *Am J Clin Pathol* 2004; 121:557-563.

131. Ramos CG, Roehl KA, Antenor JAV, **Humphrey PA**, Catalona WJ: Percent carcinoma in prostatectomy specimens is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. *J Urol* 2004; 172:137-140.

132. Collyer W, Venkatesh R, Vanlangendonck R, Morissey K, **Humphrey P**, Yan Y, Landman J : Enhanced renal cryoablation with hilar clamping and intrarenal cooling in a porcine model. *Urology* 2004; 63:1209-1212.

133. Landman J, Olweny E, Sundaram CP, Andreoni C, Collyer WC, Rehman J, Jerde TJ, Lin HK, Nunlist EH, **Humphrey PA**, Nakada SY, Clayman RV: Laparoscopic mid sagittal hemicystectomy and bladder reconstruction with small intestinal submucosa: 1-year follow-up. *J Urol* 2004;171:2450-2455.

134. Ames CD, Vanlangendonck R, Venkatesh R, Gonzales FC, Quayle S, Yan Y, **Humphrey PA**, Landman J : Enhanced renal parenchymal cryoablation with novel 17-gauge cryoprobes. *Urology* 2004; 64:173-175.

135. Gupta A, Wang HL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR, Jiang Z, **Humphrey PA**, Cheng L, Yang XJ : Expression of alpha-methylacyl coenzyme A racemase in nephrogenic adenoma. *Am J Surg Pathol* 2004; 28: 1224-1229.

136. Andriole GL, **Humphrey P**, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer*. J Urol* 2004; 172:915-919.

137. Anast JW, Andriole GL, Bismar TA, Yan Y, **Humphrey PA** : Relating biopsy and clinical variables to radical prostatectomy findings : can insignificant and advanced prostate cancer be predicted in a screening population? *Urology* 2004; 64:544-550.

138. Venkatesh R, Rehman J, Landman J, Lee D, Ragab ME, Sundaram CP, **Humphrey PA**, Clayman RV. Determination of cell viability after laparoscopic tissue stapling in a porcine model. *J Endourol* 2005; 19: 744-747.

139. Gokden N, Roehl KA, Catalona W, **Humphrey PA** : High-grade prostatic intraepithelial neoplasia in needle biopsy as a risk factor for detection of adenocarcinoma : Current level of risk in a screening population.  *Urology* 2005; 65:538-542.

141. Hameed O, Sublett J, **Humphrey PA** : Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma : A comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. *Am J Surg Pathol* 2005; 29:579-587.

142. Suh N, Yang XJ, Tretiakova MS, **Humphrey PA,** Wang HL : Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. *Mod Pathol* 2005; 18:1217-1224.

143. Fine SW, **Humphrey PA**, Dehner LP, Amin MB, Epstein JI : Urothelial neoplasms in patients 20 years or younger : A clinicopathologic analysis using World Health Organization 2004 Consensus Classification*. J Urol* 2005; 174:1976-1980.

144. Hameed O, **Humphrey PA** : p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides : A viable approach in the diagnosis of small atypical foci that are lost on block sectioning. *Am J Clin Pathol* 2005; 124:708-715.

145. Evans AJ, **Humphrey PA**, Belani J, van der Kwast TH, Srigley JR : Large cell neuroendocrine carcinoma of the prostate. A clinicopathologic summary of seven cases of a rare manifestation of advanced prostate cancer.  *Am J Surg Pathol* 2006; 30:684-693.

146. **Humphrey PA,** Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW : Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer : Results from Cancer and Leukemia Group B 150005/9480. *Clin Genitourinary Cancer* 2006; 4:269-274.

147. Hameed O, **Humphrey PA** : Stratified epithelium in prostatic adenocarcinoma : A mimic of high-grade prostatic intraepithelial neoplasia. *Mod Pathol* 2006; 19:899-906.

148. Weld KJ, Hruby G, **Humphrey PA**, Ames CD, Landman J : Precise characterization of renal parenchymal response to single and multiple cryoablation probes*. J Urol* 2006; 176:784-786.

149. Weld KJ, Ames CD, Hruby G, **Humphrey PA**, Landman J : Evaluation of a novel knotless self-anchoring suture material for urinary tract reconstruction. *Urology* 2006; 67:1133-1137.

150. Wild PJ, Giedl J, Stoehr R, Junker K, Boehm S, van Oers JMM, Zwartoff EC, Blaszyk H, Fine SW, **Humphrey PA**, Dehner LP, Amin MB, Epstein JI, Hartmann A : Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. *J Pathol* 2007; 211:18-25.

151. Turbiner J, Amin MB, **Humphrey PA**, Srigley JR, De Leval L, Radhakrishanan A, Oliva, E : Cystic nephroma and mixed epithelial and stromal tumor of kidney : A detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor as a unifying term. *Am J Surg Pathol* 2007; 31:489-500.

152. Hruby GW, Marruffo FC, Durak E, Collins SM, Pierorazio P, **Humphrey PA**, Mansukhani M, Landman J:    Evaluation of surgical energy-devices for vessel sealing and peripheral energy spread in a porcine model: Harmonic Ace, Harmonic LCS-C5, Ligasure 5, and a Prototype Bipolar Trissector*.   J Urol* 2007; 178:2689-2693.

153. Prasad SR, Sahani DV, Mino-Kenudson M, Narra VR, **Humphrey PA**, Menias CO, Chintapalli KN : Neoplasms of the perivascular epithelioid cell involving the abdomen and the pelvis : cross-sectional imaging findings. *J Comput Assist Tomogr* 2007; 31:688-696.

154. Brimo F, Vollmer RT, Corcos J, **Humphrey PA**, Bismar TA : Outcome for repeated biopsy of the prostate : roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia. *Am J Clin Pathol* 2007; 128: 648-651.

155. Bismar TA, **Humphrey P**, Vollmer RT : Information content of five nomograms for outcomes in prostate cancer. *Am J Clin Pathol* 2007; 28: 803-807.

156. Rosen DA, Hooton TM, Stamm WE, **Humphrey PA**, Hultgren SJ : Detection of intracellular bacterial communities in human urinary tract infection. *PLoS Med* 2007; 4:e329, 1-10.

157. Skolarus, TA, Serrano MF, Berger DA, Bullock TL, Yan Y, Humphrey PA, Kibel AS: The distribution of histologic subtypes of renal tumors by decade of life using the 2004 WHO classification*. J Urol* 2008; 179:439-443.

158. Phillips CK, Hruby GW, Durak E, Lehman DS, **Humphrey PA**, Mansukhani MM, Landman J: Tissue response to surgical energy devices. *Urology* 2008; 71:744-748.

159. Berger DA, Megwalu II, Vlahiotis A, Radwan MH, Serrano MF, **Humphrey PA**, Piccirillo JF, Kibel AS : Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. *Urology* 2008; 72:359-363.

160. Serrano MF, Katz M, Yan Y, Kibel AS, **Humphrey PA**: Percentage of high-grade renal cell carcinoma as a prognostic indicator in renal cell carcinoma.  *Cancer* 2008; 113: 477-483.

161. Brimo F, Vollmer RT, Corcos J, Kotar K, Begin LR, **Humphrey PA**, Bismar TA: Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. *Histopathology* 2008; 53:177-183.

162. Latour M, Amin MB, Billis A, Egavad L, Grignon DJ, **Humphrey PA**, Reuter VE, Sakr WA, Wheeler TM, Yang XJ, Epstein JI. Grading of invasive cribriform carcinoma on prostate needle biopsy: An interobserver study among experts in genitourinary pathology. *Am J Surg Pathol* 2008; 32:1532-1539.

163. Benway BM, Daiz DL, Katz MD, Vardi IY, Chavla NT, Desai AC, Badwan KH, Maxwell KL, Baca G, **Humphrey PA**, Bhayani SB, Figenshau RS. Open versus laparoscopic retroperitoneal lymph node dissection: Assessing adequacy of dissection in a porcine model. *J Endourol* 2009; 23:485-488.

164. Xu J, **Humphrey PA**, Kibel AS, Snyder AZ, Narra VR, Ackerman JJ, Song SK. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. *Magn Reson Med* 2009; 61:842-850.

165. Natalin RA, Hruby GW, Okhunov Z, Singh H, Phillips CK, **Humphrey PA**, Gupta M, Landman J. Pilot study evaluating ureteric physiological changes with a novel ‘ribbon stent’ design using electromyographic and giant magnetoresistive sensors. *BJU Int* 2009; 103:1128-1131.

166. Hameed O, **Humphrey PA**. Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs. new recut sections from the block: A prospective comparison. *Am J Clin Pathol* 2009; 131:683-687.

167. Cao D, **Humphrey PA**, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. *Cancer* 2009; 115:2640-2651.

168. Cao D, Li J, Guo CC, Allan RW, **Humphrey PA**. SALL4 is a novel diagnostic marker for testicular germ cell tumors. *Am J Surg Pathol* 2009; 33:1065-1077.

169. Kibel AS, Dehdashti F, Matthew K, Aleksandra K, Grubb RL, **Humphrey P**, Siegel C, Cao D, Gao F, Siegel BA. Prospective study of FDG-PET/CT for staging of muscle-invasive bladder carcinoma. *J Clin Oncol* 2009; 27:4314-4320.

170. Sanati S, Watson MA, Salavaggione AL, **Humphrey PA**. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol 2009; 22:1273-1279.

171. Song H, Zhang B, Watson MA, **Humphrey PA**, Lim H, Milbrandt J. Loss of Nkx3.1 leads to activation of discrete downstream target genes during prostate tumorigenesis. *Oncogene* 2009; 28:3307-3319.

172. Skolarus TA, Serrano MF, Grubb RL 3rd, Katz MD, Bullock TL, Gao F, **Humphrey PA,** Kibel AS. Effect of reclassification on the incidence of benign and malignant renal tumors. *J Urol* 2010 183:455-458.

173. Van der Kwast TH, Evans A, Lockwood G, Tkachuk D, Bostwick DG, Epstein JI, **Humphrey PA**, Montironi R, Van Leenders GJ, Pihl CG, Neetens I, Kujala PM, Laurila M, Mazerolles C, Bubendorf L, Finelli A, Watson K, Srigley J. Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. *Am J Surg Pathol* 2010; 34:169-177.

174. Katz MD, Serrano MF, Grubb RL 3rd, Skolarus TA, Gao F, **Humphrey PA**, Kibel AS. Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. *J Urol* 2010; 183:909-914.

175. Yaskiv O, Cao D, **Humphrey PA**. Microcystic adenocarcinoma of the prostate. A variant of pseudohyperplastic and atrophic patterns. *Am J Surg Pathol* 2010; 34:556-561.

176. Cao D, Kibel AS, Gao F, Tao Y, **Humphrey PA**. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. *Am J Surg Pathol* 2010; 34:459-463.

177. Owen HC, Giedl J, Wild PJ, Fine SW, **Humphrey PA**, Dehner LP, Amin MB, Epstein JI, Blaszyk H, Hughes D, Hartmann A, Stoehr R, Catto JW. Low frequency of epigenetic events in urothelial tumors in young patients. *J Urol* 2010; 184; 459-463.

178. Roma AA, **Humphrey PA**. Bile duct-like differentiation in teratoma : a clinicopathologic and immunohistochemical study. *Ann Diagn Pathol* 2010; 14:402-407.

179. Katz MD, Serrano MF, **Humphrey PA**, Grubb RL 3rd, Skolarus TA, Gao F, Kibel AS. The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. *Urol Oncol* 2011; 29:738-744.

180. Cao D, **Humphrey PA**, Gao F, Tao Y, Kibel AS. The ability of linear length of positive margins in radical prostatectomy specimens to predict biochemical recurrence.  *Urology* 2011; 77:1409-1415.

181. Wang J, Zhang K, Grabowska D, Li A, Dong Y, Day R, **Humphrey P**, Lewis JS Jr, Kladney R, Arbeit JM, Weber JD, Chung CH, Michel LS. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. *Mol Cancer Res* 2011; 9:1686-1696.

182. Mogal AP, Watson MA, Ozslok F, Salavaggione L, **Humphrey PA**. Gene expression profiles and differential cytoglobin expression in atrophy and adenocarcinoma of the prostate. *The Prostate* 2012; 72:931-937.

183. Hudson J, Cao D, Vollmer RT, Kibel AS, Grewal S, **Humphrey PA**. Foamy gland adenocarcinoma of the prostate : Incidence, Gleason grade, and early clinical outcome. *Hum Pathol* 2012; 43:974-979.

184. Gottipati S, Warncke J, Vollmer R, **Humphrey PA**. Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue. *Am J Surg Pathol* 2012; 36:900-907.

185. Roma AA, **Humphrey PA.** Prostatic tissue in testicular teratoma. A clinicopathologic and immunohistochemical study. *Ann Diagn Pathol* 2013; 17:10-13.

186. Lin C, Yin Y, Stemler K, **Humphrey P**, Kibel AS, Mysorekar IU, Ma L. Constitutive beta-catenin activation induces male-specific tumorigenesis in the bladder urothelium. *Cancer Res* 2013, 73:5914-5925.

187. Benesh EC. **Humphrey PA**, Wang Q, Moley KH. Maternal high-fat diet induces hyperproliferation and alters Pten/Akt signaling in prostates of offspring. *Sci Rep* 2013; 3:3466; DOI:10.1038/srep03466.

188. Warrick J, **Humphrey PA**. Foamy gland carcinoma of the prostate in needle biopsy : Incidence, Gleason grade, and comparative alpha-methylacyl-CoA racemase vs. ERG expression. *Am J Surg Pathol* 2013, 37:1709-1714.

189. Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, **Humphrey PA**, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, Egevad L. Diagnostic criteria for ductal adenocarcinoma of the prostate. Interobserver variability among 20 expert uropathologists. *Histopathology* 2014; 65:216-227.

190. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, **Humphrey PA**, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG. Intraductal carcinoma of the prostate : interobserver reproducibility survey of 39 urologic pathologists**.** *Ann Diagn Pathol* 2014 18:333-342.

191. **Humphrey PA**, Hickey TP, Riley, TL, Mabie JE, Strother M, Andriole GL. Modified Gleason grade of prostatic adenocarcinomas detected in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *J Urol* 2014; 192:391-395.

192. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, **Humphrey P**, Taylor JR, Newman VA, Barbier L, Rock CL, Marshall J. A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men’s Eating and Living (MEAL) Study (CALGB 70807) [Alliance]). *Contemp Clin* *Trial* 2014; 38:198-203

193. Andrews C, **Humphrey PA**. Utility of ERG vs. AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue. *Am J Surg Pathol* 2014; 38: 1007-1012.

194. Perrino CM, Hucthagowder V, Evenson M, Kulkarni S, **Humphrey PA**. Genetic alterations in renal cell carcinoma with rhabdoid features. *Hum Pathol* 2015, 46: 9-16.

195. Manda KR, Tripathi P, His AC, Ning J, Ruzinova M, Liapis H, Bailey M, Zhang H, Maher CA, **Humphrey PA**, Andriole GL, Ding L, Chen F. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. *Oncogene* 2016, 35:3282-3292.

196. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Comperat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, **Humphrey PA**, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason grade 4 prostate adenocarcinoma patterns : An inter-observer agreement study among genitourinary pathologists. *Histopathology* 2016, 69:441-449.

197. Weyerer V, Schnecekenpointner R, Filbeck T, Burger M, Hofstaeder F, Wild PJ, Fine SW, **Humphrey PA**, Dehner LP, Amin MB, Ruschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J. Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. *J Cancer* 2017; 8: 323-331.

198. Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, **Humphrey PA**, Weinreb JC, Schulam PG, Sprenkle PC. Negative multi-parametric MRI of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy. *Urology* 2017; 105:118-122.

199. Syed JS, Nawaf CB, Rosoff J, Bryson C, Nguyen KA, Suarez-Sarmeinto A, Serrano M, Kibel AS, **Humphrey P**, Shuch B, Adeniran AJ. Adverse pathologic characteristics in the small renal mass : Implications for active surveillance. *Can J Urol* 2017; 24:8759-8764.

200. Syed JS, Nguyen KA, Nawaf CB, Bhagat AM, Huber S, Levi A, **Humphrey P**, Weinreb JC, Schulam PG, Sprenkle PC. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound-targeted biopsy in patients with solitary PI-RADS v2-score lesion. *Urol Oncol* 2017; 35:542.e19-542.e24.

201. Fu L, Hwang M, Adeniran AJ, **Humphrey PA**. Proliferation index of different Gleason pattern 4 histomorphologies and associated pattern 3 adenocarcinoma of the prostate. *Hum Pathol* 2017; 70: 1-5.

202. Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, **Humphrey PA**, Hornblad J, Ickowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney J, Oxley J, Pan CC, Samaratunga H, Srigely JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M. Utility of pathology imagebase for standardization of prostate cancer grading. *Histopathology* 2018; 73: 8-18.

203. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, **Humphrey P**, Taylor J, Marshall J. The Men’s Eating and Living (MEAL) Study (CALGB 70807) [Alliance]) : Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer. *BJU Int* 2018 121:534-539.

204. Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, **Humphrey P**, Dancik GM, Liu Z, Kluger H, Shuch B. Genomic heterogeneity and the small renal mass. *Clin Cancer Res* 2018; 24:4137-4144.

205. Martin DT, Ghabili K, Levi A, **Humphrey PA**, Sprenkle PC. Prostate cancer genomic classifier relates more strongly to Gleason grade group than PI-RADS score in multi-parametric prostate MRI-ultrasound fusion targeted biopsies. *Urology* 2019; 125:64-72.

206. Hwang MJ, Bryant KG, Seo JH, Liu Q, **Humphrey PA**, Melnick MAC, Altieri DC, Robert ME. Syntaphilin is a novel biphasic biomarker of aggressive prostate cancer and a metastasis predictor. *Am J Pathol* 2019; 189:1180-1189.

207. Kench JG, Judge M, Delahunt B, **Humphrey PA**, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Egevad L. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: Updated recommendations from the International Collaboration on Cancer Reporting. *Virchows Archiv* 2019, 475:263-277.

208. Yang C, Shuch B, Serrano M, Kibel AS, Nawaf C, Vollmer R, **Humphrey PA**, Adeniran AJ. Adverse Histopathologic Characteristics in small clear cell renal cell carcinomas have negative impact of prognosis: A study of 631 cases with clinical follow-up. *Am J Surg Pathol* 2019; 43: 1413-1420.

209. Halabi J, Jagger BW, Salazar V, Winkler ES, White JP, **Humphrey PA**, Hirsch AJ, Streblow DN, Diamond MS, Moley K. Zika virus causes acute and chronic prostatitis in mice and macaques. *J Infect Dis* 2020; 221:1506-1517.

210. Gandhi JS, Smith SC, Paner GP, McKenney JK, Sekhri R, Osunkoya AO, Baras AS, DeMarzo AM, Cheville JC, Rafael JE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Sirohi D, Kaushal S, Sangio A, Robinson BD, Kweldam CF, **Humphrey PA**, Hansel DE, Schultz L, Magi-Galluzzi C, Przybycin CG, Shah RB, Mehra R, Kunju LP, Aron M, Kryvenko ON, Kench JG, Kuroda N, Tavora F, van der Kwast T, Grignon D, Epstein JI, Reuter VE, Amin MB. Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate : A survey of genitourinary subspecialists. *Am J Surg Pathol* 2020; 44:673-680.

211. Yang C, Shuch B, Kluger H, **Humphrey PA**, Adeniran AJ. High WHO/ISUP grade and unfavorable architecture rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis. *Am J Surg Pathol* 2020; 44:582-593.

212. Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, **Humphrey PA**,Iczkowski KA, Kench JG, Kristiansen G, van der Kwast TH, Leite KRM,McKenney JK, Oxley J, Pan C-C, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, Varma M, Zhou M, Lindberg J, Lindskog C, Ruusuvuori P, Wahlby C, Gronberg H, Rantalainen M, Egevad L, Eklund M. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. *Lancet Oncol* 2020; 21:222-232.

213. Egevad L, Swanberg D, Delahunt B, Strom P, Kartasalo K, Olsson H, Berney DM, Bostwick DG, Evans AJ, **Humphrey PA**, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, McKenney JK, Oxley J, Pan C-C, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M, Eklund M. Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. *Virchows Arch* 2020; 477 ; 777-786.

214. Nagpal K, Foote D, Tan F, Liu Y, Chen P-HC, Steiner D, Manoj N, Olson N, Smith JL, Mohtashamian A, Peterson B, Amin MB, Evans AJ, Sweet J, Cheung C, van der Kwast T, Sangoi AR, Zhou M, Allan R, **Humphrey PA**, Hipp JD, Gadepalli K, Corrado GS, Peng LH, Stumpe MC, Mermel CH. Development and validation of a deep learning algorithm for Gleason grading for prostate cancer from biopsies. *JAMA Oncol* 2020; 6:1372-1380.

215. Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, Lopex Beltran A, Brimo F, Cheville JC, Colecchia M, Comperat E, Costello T, Da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, **Humphrey PA**, Jimenez RE, Khani F, Kong MX, Kryvenko ON, Kunja LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Pavlovich CP, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger D, Epstein JI. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. *Urol Oncol* 2021; 39:295.e1-295.e8.

216. McGillivray PD, Ueno D, Pooli A, Mendhiratta N, Syed JS, Nguyen KA, Schulam PG, **Humphrey PA**, Adeniran AJ, Boutros PC, Shuch B. Distinguishing benign renal tumors with an oncocytic gene expression (ONEX) classifier. *Eur Urol* 2021; 79:107-111.

217. Torres R, Olson E, Homer R, Martin DT, Levene MJ, Perincheri S, Sprenkle PC, **Humphrey PA**. Initial evaluation of rapid, direct-to-digital prostate biopsy pathology. *Arch Pathol Lab Med* 2021; 145:583-591.

218. He S, Li G, Schatzlein AG, **Humphrey PA**, Weiss RM, Uchegbu IF, Martin DT. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis. *Cell Signal* 2021; 81:109991.

219. Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, **Humphrey P**, Adeniran A, Narayan V, Bajarnason GA, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with carbozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomized open-label, phase 2 trial. *The Lancet* 2021; 397: 695-703.

220. Yang C, Shuch B, Kluger HM, Serrrano M, Kibel AS, **Humphrey PA**, Adeniran AJ. Adverse histopathologic characteristics in small papillary renal cell carcinomas have minimal impact on prognosis. *Am J Clin Pathol* 2021; 156:550-558.

221. Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng F-M, Epstein J, Fine SW, Genega EM, Hirsch MS, **Humphrey PA**, Gordetsky J, Kristian sen G, Kunju P, Magi-Galluzzi C, Gupta N, Netto GJ, Osunkoya AO, Robinson BD, Trpkov K, True LD, Troncoso P, Varma M, Wheeler T, Williamson SR, Wu A, Zhou M: Diagnosis of “cribriform” prostatic adenocarcinoma : An interobserver reproducibility study among urologic pathologists with recommendations. *Am J Cancer Res* 2021; 11:3990-4001.

222. Martin DT, Lee JS, Liu Q, Galiana G, Sprenkle PC, **Humphrey PA**, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM: Targeting prostate cancer with clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. *Nanomedicine* 2021; 40:102477.

223. Paulson N, Vollmer RT, **Humphrey PA**, Sprenkle PC, Onofrey J, Huber S, Amirkhiz K, Levi AL. Extent of high-grade prostatic adenocarcinoma in multiparametric magnetic resonance imaging-targeted biopsy enhances prediction of pathologic stage. *Arch Pathol Lab* Med 2022; 146:201-204.

224. Bulten W, Kartasalo, K, Chen, P-HC, Ström P, Pinckaers H, Nagpal K, Cai Y, Steiner DF, van Boven H, Vink R, Hulsbergen-van de Kaa C, van der Laak J, Amin MB, Evans, AJ, van der Kwast T, Allan R, **Humphrey PA**, Grönberg H, Samaratunga H, Delahunt B, Tsuzuki T, Häkkinen T, Egevad L, Demkin M, Dane S, Tan F, Valkonen M, Corrado GS, Peng L, Mermel CH, Ruusuvuori P, Litjens G, Eklund M, and the PANDA Challenge consortium: Artificial intelligence for diagnosis and Gleason grading of prostate cancer: The PANDA Challenge. *Nature Med* 2022; 28:154-163.

225. Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, **Humphrey PA**, Staib LH, Levi AW. Prediction of adverse pathology at radical prostatectomy in grade group 2 and 3 prostate biopsies using machine learning. *JCO Clin Cancer Inform* 2022; Sep 6; 6e2200016.

226. Lerner G, Tang H, Singh K, Golestani R, St Claire S, **Humphrey PA**, Lannin D, Janostiak R, Harigopal M. AMACR expression is a potential diagnostic marker in apocrine lesions of breast, and is associated with high histologic grade and lymph node metastases in some invasive apocrine breast cancers. *Clin Breast Cancer* 2023 Feb;23(2):199-210.

**Chapters, Books, and Reviews**

227. Colapinto EV, Lee YS, McLendon RE, **Humphrey PA,** Zalutsky MR, Friedman HS, Pegram CN, Bigner SH, Bullard DE, Wikstrand CJ, Bigner DD: The applications of monoclonal antibodies in neuro-oncology. In Chatel M, Darcel F, Pecker J, eds: Brain Oncology: Biology, Diagnosis and Therapy, Proceedings of the International Meeting on Brain Oncology. The Netherlands: Martinus Nijhoff, 1987, pp 121-124.

228. **Humphrey PA**: The role of tumor markers in the early detection of cancer. *Semin Surg Oncol* 1989;5:186-193.

229. Lee YS, Wikstrand CJ, **Humphrey PA**, Bigner SH, Friedman HS, Vrionis F, Bigner DD: In vitro growth of brain tumors. In Salcman M, ed: Neurobiology of Brain Tumors, Volume 4. Baltimore: Williams & Wilkins, 1990, pp 163-183.

230. Wikstrand CJ, Fredman P, Svennerholm L, **Humphrey PA**, Bigner SH, Bigner DD: Monoclonal antibodies to malignant human gliomas. *Mol Chem Neuropathol* 1992;17:137-146.

231. Thrasher JB, Rajan RR, Perez LM, **Humphrey PA**, Anderson EE. Pheochromocytoma of urinary bladder: Contemporary methods of diagnosis and treatment options.  *Urology* 1993;41:435-439.

232. **Humphrey PA**, Walther PJ: Adenocarcinoma of the prostate. I. Tissue sampling considerations. *Am J Clin Pathol* 1993; 99:746-759.

233. **Humphrey PA**, Walther PJ: Adenocarcinoma of the prostate. II. Tissue prognosticators. *Am J Clin Pathol* 1993;100:256-269.

234. Ostrowski LE, Bigner SH, **Humphrey PA**, Bigner DD: Genetic alterations and gene expression in human malignant glioma. In Pretlow TG, Pretlow TP, eds: Biochemical and Molecular Aspects of Selected Cancers, Vol 2. San Diego, CA, Academic Press, 1994, 143-168.

235. **Humphrey PA**: p53: Mutations and immunohistochemical detection, with a focus on alterations in urologic malignancies. In Weinstein RS, Graham AR, Anderson RE, Benson ES, Cotran RS, Jarett L, Wick MR, Zumwalt RE, eds: Advances in Pathology and Laboratory Medicine, Vol. 7. Chicago: Mosby YearBook, 1994, pp. 579-606.

236. Netto GJ**, Humphrey PA**: Molecular biologic aspects of human prostatic carcinoma. *Am J Clin Pathol* 1994;102 (Suppl 1):S57-S64.

237. Wick MR, Ritter J, **Humphrey PA**, Swanson PE: Immunopathology of non-neoplastic skin diseases: A brief review. *Am J Clin Pathol* 1996; 105:417-429.

238. Von Eschenbach AC, Brawer MK, di Sant-Agnese PA, **Humphrey PA**, Mahran H, Murphy GP, Sebo TJ, Veltri R: Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. *Cancer* 1996;78:372-375.

239. Wick MR, Ritter JH, **Humphrey PA**: Sarcomatoid carcinomas of the lung: A clinicopathologic review*. Am J Clin Pathol* 1997;108:40-53.

240. Wick MR, Ritter JH, **Humphrey PA**, Nappi O: Clear cell neoplasms of the endocrine system and thymus. *Semin Diagn Pathol* 1997; 14:183-202.

241. Smith DS, **Humphrey PA**, Catalona WJ: The early detection of prostate carcinoma with prostate specific antigen. The Washington University experience. *Cancer* 1997; 80:1852-1856.

242. **Humphrey PA**: Clear cell neoplasms of the urinary tract and male reproductive system. *Semin Diagn Pathol* 1997; 14:240-252.

243. **Humphrey PA,** Vollmer RT: Relationships between serum prostate specific antigen and histopathological appearances of prostatic carcinoma. In Foster CS, Bostwick DG, eds: Pathology of the Prostate, Major Problems in Pathology Series. Philadelphia: W.B. Saunders Co., 1997, pp. 253-281.

244. Wick MR, **Humphrey PA**, Ritter JA, eds: Pathology of Pseudoneoplastic Lesions. Philadelphia : Lippincott-Raven Press, 621 pp, 1997.

245. Wick MR, Ritter JH, **Humphrey PA**: Pseudoneoplastic lesions of the skin and superficial soft tissues. In Wick MR, Humphrey PA, Ritter JH, eds: Pathology of Pseudoneoplastic Lesions, Philadelphia: Lippincott-Raven, 1997, pp. 545-585.

246. **Humphrey PA**, Wick MR: Pseudoneoplastic conditions of the breast and endocrine system. In Wick MR, Humphrey PA, Ritter JH, eds: Pathology of Pseudoneoplastic Lesions, Philadelphia: Lippincott-Raven, 1997, pp. 223-275.

247. Naughton CK, Nadler RB, Basler JW, **Humphrey PA**: Leydig cell hyperplasia: A review. *Br J Urol* 1998; 81:282-287.

248. Ritter JH, **Humphrey PA**, Wick MR: Malignant neoplasms capable of simulating inflammatory (myofibroblastic) pseudotumors and tumefactive fibroinflammatory lesions: Pseudopseudotumors. *Semin Diagn Pathol* 1998; 15:111-132.

249. Coffin CM, **Humphrey PA**, Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor. *Semin Diagn Pathol* 1998; 15:85-101.

250. Thorson P, **Humphrey PA** : Minimal adenocarcinoma in prostate needle biopsy tissue. *Am J Clin Pathol* 2000; 114:896-909.

251. Kibel AS, **Humphrey PA** : Latent prostate carcinoma in a screened population. *Eur Urol* 2001; 39(suppl): 35-36.

252. **Humphrey PA** : Pathology of malignant tumors of the spermatic cord. In Hamdy FC, Basler JW, Neal DE, Catalona WJ, eds: Management of Urologic Malignancies, London: Churchill Livingstone, 2002, pp. 483-486.

253. **Humphrey PA** : Pathology of malignant tumors of the scrotum. In Hamdy FC, Basler JW, Neal DE, Catalona WJ, eds: Management of Urologic Malignancies, London : Churchill Livingstone, 2002, pp. 491-493.

254. **Humphrey PA**: Pathology of carcinoma of the penis. In Hamdy FC, Basler JW, Neal DE, Catalona WJ, eds: Management of Urologic Malignancies, London : Churchill Livingstone, 2002, pp. 507-512.

255. **Humphrey PA** : Prostate Pathology. Chicago : ASCP Press, 556 pages, 2003.

256. Amin MB, Grignon DJ, **Humphrey PA**, Srigley JR : Gleason Grading of Prostate Cancer : A Contemporary Approach. Philadelphia : Lippincott Williams & Wilkins, 116 pp, 2004.

257. **Humphrey PA** : Gleason grading and prognostic factors in carcinoma of the prostate. *Mod Pathol* 2004; 17:292-306.

258. **Humphrey PA** : Gleason grading of carcinoma of the prostate. *Pathol Int* 2004; 54 (Suppl 1) : S615-S618.

259. **Humphrey PA** : Urinary bladder pathology 2004 : An update. *Ann Diagn Pathol* 2004; 8:380-389.

260. Prasad SR, **Humphrey PA**, Menias CO, Middleton WD, Siegel MJ, Bae KT, Heiken JP : Neoplasms of the renal medulla : Radiologic-pathologic correlation. *RadioGraphics* 2005; 25:369-380.

261. Hameed O, **Humphrey PA** : Immunohistochemistry in diagnostic surgical pathology of the prostate. *Semin Diagn Pathol* 2005; 22:88-104.

262. **Humphrey PA:** The prostate gland. In Silverberg SS, DeLillis RA, Frable WJ, LiVolsi VA, Wick MR, eds: Silverberg’s Principles and Practice of Surgical Pathology and Cytopathology, 4th edition, Philadelphia: Elsevier Science, 2006, pp. 1791-1828.

263. **Humphrey PA** : Non-adenocarcinomatous cancers of the prostate. In Kirby RS, Partin AW, Feneley MR, Parsons JK, eds : Prostate Cancer. Principles and Practice, New York : Taylor and Francis, 2006, pp. 135-142.

264. Hameed O, **Humphrey PA** : Immunohistochemistry in the diagnosis of minimal prostate cancer. *Curr Diagn Pathol* 2006; 12:279-291.

265. Prasad SR, **Humphrey PA,** Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC, Chintapalli KN : Common and uncommon histologic subtypes of renal cell carcinoma : Imaging spectrum with pathologic correlation. *RadioGraphics* 2006; 26: 1795-1810.

266. **Humphrey PA** : Diagnosis of adenocarcinoma in prostate needle biopsy tissue. *J Clin Pathol* 2007; 60:35-42.

267. Prasad SR, Narra VR, Shah R, **Humphrey PA**, Jagirdar J, Catena JR, Dalrymple NC, Siegel CL : Segmental disorders of the nephron : histopathological and imaging perspective. *Br J Radiol* 2007; 80:593-602.

268. **Humphrey PA**, Dehner LP, Pfeifer JD : The Washington Manual of Surgical Pathology. Philadelphia : Lippincott Williams and Wilkins, 2008.

269. **Humphrey PA** : Genital skin and urethral anatomy. In Brandes SB, ed: Urethral Reconstructive Surgery. New Jersey, The Humana Press Inc., 2008, pp. 1-8.

270. Hameed O, **Humphrey PA**. Pseudoneoplastic mimics of prostate and bladder carcinomas. *Arch Pathol Lab Med* 2010; 134:427-443.

271. **Humphrey PA**, Andriole GA. Prostate cancer diagnosis. *Missouri Med* 2010; 107:107-112.

272. Epstein JI, Cubilla AL, **Humphrey PA**. Tumors of the Prostate Gland, Seminal Vesicles, Penis, and Scrotum. Washington DC : Armed Forces Institute of Pathology, 2011.

273. **Humphrey PA**. Histologic variants of prostate carcinoma and their significance.  *Histopathology* 2012; 60:59-74.

274. **Humphrey PA**, Dehner LP, Pfeifer JD : The Washington Manual of Surgical Pathology. 2nd edition. Philadelphia : Lippincott Williams and Wilkins, 2012.

275. **Humphrey PA**, Manivel C, Young RH : Neoplastic Mimics in Genitourinary Pathology. New York : Demos Medical Publishing, 2013.

276. **Humphrey PA** : Male urethra and external genitalia anatomy. In Brandes SB, ed: Advanced Male Urethral and Genital Reconstructive Surgery. New Jersey, The Humana Press Inc., 2013, 2nd ed. pp. 17-24.

277. **Humphrey PA** : Cancers of the male reproductive tract. In World Health Organization World Cancer Report 2014, IARC Press, 2014, pp. 453-463.

278. **Humphrey PA** : Non-neoplastic diseases of the prostate and seminal vesicles.

In Amin MB, Grignon D, Srigley JR, Eble JN, eds : Urological Pathology. Wolters Kluwer Health. 2014, pp. 491-558.

279. **Humphrey PA** : Surgical pathology of the prostate gland. In Wick MR, ed: Silverberg’s Principles and Practice of Surgical Pathology and Cytopathology, 5th edition, Philadelphia: Elsevier Science, 2015.

280. **Humphrey PA**, Wick MR, Suriawinata AA. In : Suriawinata AA, ed: Neoplastic Mimics in Gastrointestinal and Liver Pathology. New York : Demos Publishing, 2015, pp. 195-210.

281. Adeniran AO, **Humphrey PA**. Morphologic updates in prostate pathology. *Surg Pathol Clin* 2015, 8:539-560 (review).

282. Adeniran AO, Shuch B, **Humphrey PA.** Hereditary renal cell carcinoma syndromes : clinical, pathologic, and genetic features. *Am J Surg Pathol* 2015, 39: e1-e18 (review).

283. Moch H, **Humphrey PA**, Ulbright TM, Reuter VE. Tumours of the Urinary System and Male Genital Organs. Pathology and Genetics. World Health Organization Classification of Tumours. IARC Press, Lyon, France, 2016.

284. Moch H, Cubilla AL, **Humphrey PA**, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs – Part A. Renal, penile, and testicular tumours. *Eur Urol* 2016, 70:93-105.

285. **Humphrey PA**, Moch H, Cubilla A, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs – Part B. Prostate and bladder tumours. *Eur Urol* 2016, 70:106-119.

286. Brimo F, Srigley JR, Ryan CJ, Choyke PL, **Humphrey PA**, Barocas DA, Brookland RK, Buyyounouski MK, Fine SW, Halabi S, Hamstra DA, Kattan MW, McKenney JK, Mason MD, Oh WK, Pettaway CA, Touijer KA, Zelefsky MJ, Sandler HM, Amin MB, Lin DW: Testis. In : Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LM, eds : AJCC Cancer Staging Manual , 2017, 8th ed. pp. 727-735.

287. **Humphrey PA.** Histopathology of Prostate Cancer. In Shen MM, Rubin MA, eds: Prostate Cancer. *Cold Spring Harb Perspect Med*, 2017, 7:1-21.

288. **Humphrey PA**. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. *Mod Pathol* 2018, Jan 31 (S1) : S64-70.

289. Pfeifer JD, **Humphrey PA**, Ritter JH, Dehner LP. The Washington Manual of Surgical Pathology. 3nd edition. Philadelphia : Lippincott Williams and Wilkins, 2020.

290. Yang C, **Humphrey PA**. False negative histopathologic diagnosis of prostatic adenocarcinoma. *Arch Pathol Lab Med* 2020; 144:326-334.

291. Parwani AV, Patel A, Zhou M, Cheville JC, Tizhoosh H, **Humphrey P**, Reuter VE, True L. An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS). *J Pathol Inform* 2023; 14:100177, 13 pages*.*

292. Kumar D, **Humphrey PA**. PIN-like adenocarcinoma. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/prostatepinlikeadeno.html>. Posted April 27, 2023.

**Peer-Reviewed Educational Materials**

293. **Humphrey PA**. Hormonal Therapy. eMedicine from WebMD. Updated April 07, 2010. Available at: <http://emedicine.medscape.com/article/1612087-overview>.

294. **Humphrey PA**. Squamous Cell Carcinoma of the Prostate. eMedicine from WebMD. Updated April 20, 2010. Available at <http://emedicine.medscape.com/article/1612111-overview>.

**Invited Editorials and Commentaries**

295. **Humphrey PA**: Tissue sampling in the era of cost constraints. *Am J Clin Pathol* 1994;101:247-248.

296.Mills SE, Kempson RL, Fechner RE, Frierson HF Jr., Wick MR, Dehner LP, Swanson PE, **Humphrey PA**: Guardians of the wax ... and the patient.  *Mod Pathol* 1995;8:699-700.

297. **Humphrey PA:** Editorial comment on prostatic intraepithelial neoplasia. *J Urol* 1996;156:1054-1055.

298. Keetch DW, **Humphrey PA**: Patient age and prostate cancer. *Am J Clin Pathol* 1997; 107:265-267.

299. **Humphrey PA** : Prostate cancer in the serum prostate specific antigen era. *Mayo Clin Proceed* 1998; 73:489-490.

300. Andriole GL, **Humphrey PA**, Serfling RJ, Grubb RL : High-grade prostate cancer in the Prostate Cancer Prevention Trial : Fact or Artifact? *J Natl Cancer Inst* 2007; 99:1355-1356.

301. **Humphrey PA**. Tumor amount in prostatic tissues in relation to patient outcome and management. *Am J Clin Pathol* 2009, 131:7-10.

302. **Humphrey PA**. Diagnostic anatomic pathology in the era of molecular medicine. *Missouri Med* 2010; 107:76-77.

303. **Humphrey PA.** Advances, Timely Topics, and Updates in Genitourinary Pathology. *J Clin Transl Pathol* 2023. Doi: 10.14218/JCPT.2022.00034.

**Practice Guidelines, Standards and Consensus Statements**

304.Amin M, Boccon-Gibod L, Egevad L, Epstein JI, **Humphrey PA**, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R : Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. *Scand J Urol Nephrol* (Suppl) 2005; 216:20-33.

305.Epstein JI, Amin M, Boccon-Gibod L, Egevad L, **Humphrey PA**, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R : Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. *Scand J Urol Nephrol* (Suppl) 2005; 216:34-63.

306.Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, **Humphrey PA**, Mikuz G, Newling D, Nilsson S, Sakr W, Wheeler TM, Montironi R : Prognostic and predictive factors in prostate cancer : Historical perspectives and recent international consensus initiatives. *Scand J Urol Nephrol* (Suppl) 2005; 216:8-19.

307.Srigley JR, Amin MB, Epstein JI, Grignon DJ, **Humphrey PA**, Renshaw AA, Wheeler TM : Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. *Arch Pathol Lab Med* 2006; 130: 936-946.

308.Srigley JR, **Humphrey PA**, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. *Arch Pathol Lab Med* 2009; 133:1568-1576.

309.Epstein JI, Srigley J, Grignon D, **Humphrey P** : Recommendations for the reporting of prostate carcinoma. *Hum Pathol* 2007; 38: 1305-1309.

310. McKenney JK, Amin MB, Epstein JI, Grignon DJ, Oliva E, Reuter VE, Srigley JR, **Humphrey PA**. Protocol for the examination of specimens from patients with carcinoma of the urethra. *Arch Pathol Lab Med* 2010; 134:345-350.

311.Srigley JR, Amin MB, Delahunt B, Campbell SC, Chang A, Grignon DJ, **Humphrey PA**, Leibovich BC, Montironi R, Renshaw AA, Reuter VE. Protocol for examination of specimens from patients with invasive carcinoma of renal tubular origin. *Arch Pathol Lab Med* 2010; 134:e25-30.

312. Velazquez EF, Amin MB, Epstein JI, Grignon DJ, **Humphrey PA**, Pettaway CA, Renshaw AA, Reuter VE, Srigley JR, Cubilla AL. Protocol for examination of specimens from patients with carcinoma of the penis. *Arch Pathol Lab Med* 2010; 134; 923-929.

313. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffins DF, **Humphrey PA**, van der Kwast TH, Montironi R, Delahunt B, Egevad L, Srigley JR, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4 : seminal vesicle and lymph nodes. *Mod Pathol* 2011; 24 : 39-47.

314. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Wheeler TM, Srigley JR, Egevad L, **Humphrey PA**. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 3 : extraprostatic extension, lymphovascular invasion and locally advanced disease. *Mod Pathol* 2011; 24:26-38.

315. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, **Humphrey PA**, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1 : specimen handling. *Mod Pathol* 2011; 24:6-15.

316. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, **Humphrey PA**, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 2 : T2 substaging and prostate cancer volume. *Mod Pathol* 2011; 24:16-25.

317. Tan PH, Cheng L, Srigley JR, Griffiths D, **Humphrey PA**, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 5 : surgical margins. *Mod Pathol* 2011; 24:48-57.

318. Fine SW, Amin MB, Berney DM, Bjartell A, Egevad L, Epstein JI, **Humphrey PA**, Magi-Galluzzi C, Montironi R, Stief C. A contemporary update on pathology reporting for prostate cancer : biopsy and radical prostatectomy specimens. *Eur Urol* 2012; 62:20-39.

319. Kench JG, Delahunt B, Griffiths DF, **Humphrey PA**, McGowan T, Trpkov K, Varma M, Wheeler TM, Srigley JR. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting.  *Histopathology* 2013; 62:203-218.

320. Delahunt B, Cheville JC, Martignoni G, **Humphrey PA**, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; The Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. *Am J Surg Pathol* 2013; 37:1490-1504.

321. Amin MB, Epstein JI, Ulbright TM, **Humphrey PA**, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran, Zhou M, Argani P, Delahunt B, Berney DM, Srigley JR, Tickoo SK, Reuter, VE. Best practices recommendations in the application of immunohistochemistry in urologic pathology: Report from the International Society of Urological Pathology Consensus Conference. *Am J Surg Pathol* 2014; 38: 1017-1022.

322. Epstein JI, Egevad L, **Humphrey PA**, Montironi R, and members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application if immunohistochemistry in the prostate. Report from the International society of Urologic Pathology Consensus Conference. *Am J Surg* *Pathol* 2014; 38, e6-e19.

323. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, **Humphrey PA**, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond E. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer. *Arch Pathol Lab Med* 2014; 138:1387-1405.

324. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, **Humphrey PA**. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Definition of Grading Patterns and Proposal for a New Grading System. *Am J Surg Pathol* 2016; 40:244-252.

325. Epstein JI, Amin MB, Reuter VE, **Humphrey PA**. Contemporary Gleason grading of prostatic carcinoma : An update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol* 2017; 41: e1-7.

326. Verrill C, Perry-Keene J, Srigley JR, Zhou M, **Humphrey PA**, Lopez-Beltran A, Egevad L, Ulbright TM, Tickoo SK, Epstein JI, Comperat E, Berney DM; Members of the ISUP Testicular Tumor Panel. Intraoperative consultation and macroscopic handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. *Am J Surg Pathol* 2018; 42:e33-e43.

327. Egevad L, Judge M, Delahunt B, **Humphrey PA**, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG. Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Pathology* 2019; 51:11-20.

328. Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, Lopez Beltran A, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordestsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, **Humphrey PA**, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju P, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, JK, Netto G, Nguyen JK, Osunkoya AO, Parwani A, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. *Arch Pathol Lab Med* 2021; 145:461-493.

329. Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, **Humphrey PA**, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Hes O. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. *Mod Pathol* 2021; 24:1167-1184.

330. Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, **Humphrey PA**, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. *Mod Pathol* 2021; 34:1392-1424.

**Case Reports, Technical Notes, Letters**

331. Herzberg AJ, MacDonald JA, Tucker JA, **Humphrey PA**, Meyers WC: Primary leiomyoma of the liver. *Am J Gastroenterol* 1990; 85:1642-1645.

332. **Humphrey PA**, Vollmer RT: Sampling of prostatic tissue. *Hum Pathol* 1990;21:353.

333. **Humphrey PA**, Vollmer RT: Extramedullary hematopoiesis in the prostate. *Am J Surg Pathol* 1991;15:486-490.

334. Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, **Humphrey P**, Grignon D, Jones EC, McNeal J, Montironi R, Qian J, Ro J, Srigley J, Tetu B, Troncoso P, True L, Wheeler T, Young RH: Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate*. Am J Surg Pathol* 1994; 18:1069-1070.

335. Thrasher JB, Rajan RR, Perez LM, **Humphrey PA**, Anderson EE : Cystitis glandularis. Transition to adenocarcinoma of the urinary bladder. *N Car Med J* 1994; 55:562-564.

336. Mallow DW, **Humphrey PA**, Soper JT, Johnston WW: Metastatic lobular carcinoma of the breast diagnosed in cervicovaginal samples. A case report. *Acta Cytologica* 1997;41:549-555.

337. Colberg JW, Cai X, **Humphrey PA**: Unilateral adrenal heterotopia with renal-adrenal fusion. *J Urol* 1998; 160:116.

338. **Humphrey PA**, Zhu X, Crouch EC, Carbone JM, Keetch DW: Mass-formative atypical adenomatous hyperplasia of prostate*. J Urol Pathol* 1998 ; 9:73-81.

339. Wang H, **Humphrey PA** : Exaggerated signet-ring cell change in stromal nodule of prostate : A pseudoneoplastic proliferation. *Am J Surg Pathol,* 2002; 26:1066-1070.

340. Bhayani SB, **Humphrey PA**, Kibel AS : Renal sinus haemangioma with inferior vena cava involvement. *BJU Int* 2003; 92 Suppl 3:e53.

341. Hertel JD, **Humphrey PA**: Ductal adenocarcinoma of the prostate*. J Urol* 2011; 86:277-278.

342. **Humphrey PA**. Renal cell carcinoma with rhabdoid features. *J Urol* 2011; 186:675-676.

343. **Humphrey PA**. Micropapillary urothelial carcinoma of the urinary tract. *J Urol* 2011; 186: 1071-1072.

344. Cao D, **Humphrey PA**. Yolk sac tumor of the testis. *J Urol* 2011; 186: 1475-1476.

345. **Humphrey PA**. Atrophy of the prostate on needle biopsy and false-positive diagnosis of malignancy. *J Urol* 2011; 186: 2065-2066.

346. Abbosh PH, Grubb RL 3rd, Cao D, **Humphrey PA**. Hybrid renal tumors in Birt-Hogg-Dube syndrome. *J Urol* 2011; 186: 2413-2414.

347. **Humphrey PA**. Minimal adenocarcinoma on prostate needle biopsy and false-negative diagnosis of malignancy. *J Urol* 2012; 187 : 283-284.

348. **Humphrey PA**. Angiosarcoma of the prostate. *J Urol* 2012; 187:684-685.

349. **Humphrey PA**. Urothelial carcinoma in situ of the bladder. *J Urol* 2012; 187: 1057-1058.

350. Johnson MH, Brandes SB, **Humphrey PA**. Recurrent and metastatic malignant melanoma of the penis. *J Urol* 2012; 187: 1438-1439.

351. **Humphrey PA**. Oncocytoma of the kidney. *J Urol* 2012; 187: 1854-1855.

352. Warrick J, **Humphrey PA**. Nonspecific granulomatous prostatitis. *J Urol* 2012; 187: 2209-2210.

353. Johnson MH, Nepple KG, **Humphrey PA**. Bladder lymphoma. *J Urol* 2012; 188: 269-270.

354. **Humphrey PA**. Sarcomatoid renal cell carcinoma. *J Urol* 2012; 188: 601-602.

355. **Humphrey PA**. BCG prostatitis*. J Urol* 2012; 188: 961-962.

356. **Humphrey PA**. Gleason pattern 5 adenocarcinoma in prostate needle biopsy. *J Urol* 2012; 188: 1341-1342.

357. **Humphrey PA**. Atypical adenomatous hyperplasia (adenosis) of the prostate. *J Urol* 2012; 188: 2371-2372.

358. **Humphrey PA**. High-grade prostatic intraepithelial neoplasia in prostate needle biopsy. *J Urol* 2013; 189: 315-316.

359. Johnson MH, Grubb RL 3rd, **Humphrey PA**. Adenocarcinoma in an ileal conduit. *J Urol* 2013; 189: 697-698.

360. **Humphrey PA**. Polypoid/papillary cystitis. *J Urol* 2013; 189: 1091-1092.

361. **Humphrey PA**. Sarcomatoid carcinoma of the bladder. *J Urol* 2013; 189: 1534-1535.

362. **Humphrey PA**. Leiomyosarcoma of the epididymis. *J Urol* 2013; 189: 1907.

363. **Humphrey PA**. Prostatic adenocarcinoma metastatic to bone. *J Urol* 203; 190: 1901-1902.

364. **Humphrey PA**. Radiation cystitis with pseudocarcinomatous urothelial hyperplasia*. J Urol* 2013; 190: 2251-2252.

365. **Humphrey PA**. Fungal prostatitis caused by Coccidioides. *J Urol* 2014; 191: 215-216.

366. **Humphrey PA**. New renal cell carcinomas in the International Society of Urological Pathology Vancouver classification of renal neoplasia*. J Urol* 2014; 191: 473-474.

367. **Humphrey PA**. Grading renal cell carcinoma : The International Society of Urological Pathology grading system*. J Urol* 2014; 191: 798-799.

368. **Humphrey PA.** Pseudohyperplastic adenocarcinoma of the prostate. *J Urol* 2014; 191:1416-1417.

369. **Humphrey PA**. Choriocarcinoma of the testis. *J Urol* 2014; 192:934-935.

370. **Humphrey PA**. Urothelial carcinoma of the upper tract. *J Urol* 2014; 192:1223-1224.

371. **Humphrey PA**. Endometriosis, endocervicosis, and mullerianosis of the bladder. *J Urol* 2014*;* 192:1523-1524.

372. **Humphrey PA**. Deceptively benign appearing urothelial carcinoma. *J Urol* 2014; 192:1817-1818.

373. Fu L, **Humphrey PA**, Adeniran AO. Renal leiomyoma.  *J Urol* 2014; 193:997-998.

374. **Humphrey PA**. Cribriform adenocarcinoma of the prostate. *J Urol* 2015; 193: 1655-1656.

375. **Humphrey PA**. Prostatic-type epithelial polyp of the urethra. *J Urol* 2015; 193:2095-2096.

376. **Humphrey PA**,Shuch B. Seminoma in cryptorchid testis in prune belly syndrome.  *J Urol* 2015; 194:799-800.

377. **Humphrey PA**. Intraductal carcinoma of the prostate.  *J Urol* 2015; 194:1434-1435.

378. **Humphrey PA**. Seminal vesicle invasion by adenocarcinoma of the prostate.  *J Urol* 2015;194:1757-1758.

379. Ghahill K, Paulson N, Syed J, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, **Humphrey PA**, Sprenkle PC. Doubling of Decipher biopsy genomic score is related to disease reclassification on subsequent surveillance biopsy but not adverse features on radical prostatectomy. *Case Rep Urology* 2021; article ID 2687416, 4 pages.